<?xml version="1.0" encoding="utf-8"?>
<chapter id="c0185" version="5.3" docsubtype="chp" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd"
         xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink">
    <info>
        <ce:pii>B978-0-7234-3864-9.00037-X</ce:pii>
        <ce:doi>10.1016/B978-0-7234-3864-9.00037-X</ce:doi>
        <ce:isbn>978-0-7234-3864-9</ce:isbn>
        <ce:copyright type="full-transfer" year="2015">Elsevier Ltd</ce:copyright>
    </info>
    <ce:floats>
        <ce:figure id="f0010">
            <ce:label>Fig. 37.1</ce:label>
            <ce:caption id="ca0010">
                <ce:simple-para id="sp0010">Complications of blood transfusion.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-01-9780723436331" id="lk0010"/>
        </ce:figure>
        <ce:figure id="f0015">
            <ce:label>Fig. 37.2</ce:label>
            <ce:caption id="ca0015">
                <ce:simple-para id="sp0020">Normal haemoglobin synthesis.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-02-9780723436331" id="lk0015"/>
        </ce:figure>
        <ce:figure id="f0020">
            <ce:label>Fig. 37.3</ce:label>
            <ce:caption id="ca0020">
                <ce:simple-para id="sp0025">Characteristic features of the alpha-thalassaemias.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-03-9780723436331" id="lk0020"/>
        </ce:figure>
        <ce:figure id="f0025">
            <ce:label>Fig. 37.4</ce:label>
            <ce:caption id="ca0025">
                <ce:simple-para id="sp0035">Characteristic features of the beta-thalassaemias.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-04-9780723436331" id="lk0025"/>
        </ce:figure>
        <ce:figure id="f0030">
            <ce:label>Fig. 37.5</ce:label>
            <ce:caption id="ca0030">
                <ce:simple-para id="sp0045">General features of bone marrow failure.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-05-9780723436331" id="lk0030"/>
        </ce:figure>
        <ce:figure id="f0035">
            <ce:label>Fig. 37.6</ce:label>
            <ce:caption id="ca0035">
                <ce:simple-para id="sp0050">French–American–British (FAB) classification of AML.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-06-9780723436331" id="lk0035"/>
        </ce:figure>
        <ce:figure id="f0040">
            <ce:label>Fig. 37.7</ce:label>
            <ce:caption id="ca0040">
                <ce:simple-para id="sp0060">WHO classification of AML.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-07-9780723436331" id="lk0040"/>
        </ce:figure>
        <ce:figure id="f0045">
            <ce:label>Fig. 37.8</ce:label>
            <ce:caption id="ca0045">
                <ce:simple-para id="sp0070">Causes of renal failure in multiple myeloma.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-08-9780723436331" id="lk0045"/>
        </ce:figure>
        <ce:figure id="f0050">
            <ce:label>Fig. 37.9</ce:label>
            <ce:caption id="ca0050">
                <ce:simple-para id="sp0080">Rye classification of Hodgkin's disease.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-09-9780723436331" id="lk0050"/>
        </ce:figure>
        <ce:figure id="f0055">
            <ce:label>Fig. 37.10</ce:label>
            <ce:caption id="ca0055">
                <ce:simple-para id="sp0085">‘B symptoms’ of lymphoma.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-10-9780723436331" id="lk0055"/>
        </ce:figure>
        <ce:figure id="f0060">
            <ce:label>Fig. 37.11</ce:label>
            <ce:caption id="ca0060">
                <ce:simple-para id="sp0090">Ann Arbor staging of malignant lymphomas. Diagram shows stages I–IV. When
                    you stage a patient you give a number (I–IV) and a letter (A or B). The letter A denotes the absence
                    of B symptoms and B denotes the presence of B symptoms. For example, patients at stage IIA have
                    stage II lymphoma without B symptoms.
                </ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-11-9780723436331" id="lk0060"/>
        </ce:figure>
        <ce:figure id="f0065">
            <ce:label>Fig. 37.12</ce:label>
            <ce:caption id="ca0065">
                <ce:simple-para id="sp0095">Risk factors for venous thromboembolism.</ce:simple-para>
            </ce:caption>
            <ce:link locator="f37-12-9780723436331" id="lk0065"/>
        </ce:figure>
    </ce:floats>
    <ce:label>37</ce:label>
    <ce:title>Haematological disorders</ce:title>
    <objectives>
        <ce:section-title id="st0010">Objectives</ce:section-title>
        <ce:para id="p0010">The key learning points for this chapter:
            <ce:list id="l0010">
                <ce:list-item id="u0010">
                    <ce:label>•</ce:label>
                    <ce:para id="p0015">What is meant by ‘haematinics’.</ce:para>
                </ce:list-item>
                <ce:list-item id="u0015">
                    <ce:label>•</ce:label>
                    <ce:para id="p0020">The different types of sickle cell crisis.</ce:para>
                </ce:list-item>
                <ce:list-item id="u0020">
                    <ce:label>•</ce:label>
                    <ce:para id="p0025">The classification and causes of anaemia.</ce:para>
                </ce:list-item>
                <ce:list-item id="u0025">
                    <ce:label>•</ce:label>
                    <ce:para id="p0030">The difference between acute and chronic leukaemia.</ce:para>
                </ce:list-item>
                <ce:list-item id="u0030">
                    <ce:label>•</ce:label>
                    <ce:para id="p0035">What is meant by the Philadelphia chromosome.</ce:para>
                </ce:list-item>
                <ce:list-item id="u0035">
                    <ce:label>•</ce:label>
                    <ce:para id="p0040">The diagnosis and treatment of multiple myeloma.</ce:para>
                </ce:list-item>
                <ce:list-item id="u0040">
                    <ce:label>•</ce:label>
                    <ce:para id="p0045">The meaning and importance of ‘B symptoms’.</ce:para>
                </ce:list-item>
                <ce:list-item id="u0045">
                    <ce:label>•</ce:label>
                    <ce:para id="p0050">The different patterns of bleeding seen in haemophilia and von Willebrand's
                        disease.
                    </ce:para>
                </ce:list-item>
                <ce:list-item id="u0050">
                    <ce:label>•</ce:label>
                    <ce:para id="p0055">Inherited conditions associated with an increased risk of venous
                        thromboembolism.
                    </ce:para>
                </ce:list-item>
            </ce:list>
        </ce:para>
    </objectives>
    <ce:sections>
        <ce:section id="s0010">
            <ce:section-title id="st0015">ANAEMIA</ce:section-title>
            <ce:para id="p0060">Anaemia is a common clinical problem as it may result from many different pathological
                processes. The aetiology, clinical evaluation, complications and investigation policy have been
                considered in<ce:intra-ref xlink:href="pii:B978-0-7234-3864-9.00029-0" id="ia0010">Ch. 29</ce:intra-ref>
                . The general approach to management is outlined first, and then specific conditions are discussed in
                detail. Anaemia can be classified by the size of the red cells seen on micros- copy or by the underlying
                cause (e.g. iron deficiency, haemolysis).
            </ce:para>
            <ce:section id="s0015">
                <ce:section-title id="st0020">General approach to management</ce:section-title>
                <ce:section id="s0020">
                    <ce:section-title id="st0025">Discover the underlying cause</ce:section-title>
                    <ce:para id="p0065">Remember that there may be more than one cause of anaemia in any one patient –
                        this can catch out the unwary! For example, folate deficiency and iron deficiency may both be
                        present in coeliac disease. In some diseases, such as rheumatoid arthritis, there are several
                        potential causes of anaemia (see<ce:intra-ref xlink:href="pii:B978-0-7234-3864-9.00036-8"
                                                                      id="ia0015">Ch. 36</ce:intra-ref>).
                    </ce:para>
                </ce:section>
                <ce:section id="s0025">
                    <ce:section-title id="st0030">Treat the underlying cause</ce:section-title>
                    <ce:para id="p0070">The anaemia will recur if the underlying problem persists (e.g. peptic
                        ulceration, colonic neoplasm).
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0030">
                <ce:section-title id="st0035">Correct the anaemia</ce:section-title>
                <ce:para id="p0075">The method of correction will depend on the type of anaemia and presence of
                    complications. In general, iron, vitamin B
                    <ce:inf>12</ce:inf>
                    and folate should only be prescribed when the patient has been appropriately investigated and shown
                    to have a deficiency.
                </ce:para>
                <ce:section id="s0035">
                    <ce:section-title id="st0040">Iron replacement</ce:section-title>
                    <ce:para id="p0080">Oral iron replacement therapy (e.g. ferrous sulphate) should be continued for 3
                        months after the haemoglobin returns to normal to replace iron stores. However, in patients who
                        have deficiency due to chronic bleeding this may mask further blood loss. Side effects include
                        nausea, diarrhoea or constipation, and abdominal pain. The stools usually become very dark or
                        black. If side effects occur, the dose can be reduced or the preparation changed, for instance
                        to ferrous gluconate. IM or IV iron can be given but only if there is poor patient compliance
                        with oral therapy, severe gastrointestinal disturbance with oral therapy, malabsorption or in
                        specific situations such as patients on dialysis and some cancer patients.
                    </ce:para>
                </ce:section>
                <ce:section id="s0040">
                    <ce:section-title id="st0045">Vitamin B
                        <ce:inf>12</ce:inf>
                        replacement
                    </ce:section-title>
                    <ce:para id="p0085">Most causes of vitamin B
                        <ce:inf>12</ce:inf>
                        deficiency are due to malabsorption and so vitamin B
                        <ce:inf>12</ce:inf>
                        is given by IM injection in the form of hydroxocobalamin. Initially it is given every other day
                        for 2 weeks to replace stores. Maintenance dosing is every 3 months and is usually lifelong.
                    </ce:para>
                </ce:section>
                <ce:section id="s0045">
                    <ce:section-title id="st0050">Folate replacement</ce:section-title>
                    <ce:para id="p0090">Oral folic acid corrects anaemia and replaces stores (a higher dose may be
                        needed in malabsorption states). Lower-dose oral folic acid should be given as prophylaxis
                        against neural tube defects to women prior to conception and throughout the first 12 weeks of
                        pregnancy.
                    </ce:para>
                    <ce:para id="p0095">There is a complex relationship with cancer; trials have raised the possibility
                        of a slightly increased risk of cancer with long-term treatment, and some rare tumours are
                        folate dependent. It should be given only when there is a definite indication. It should not be
                        given alone in megaloblastic anaemia unless vitamin B
                        <ce:inf>12</ce:inf>
                        status has been shown to be normal, as although it will partially normalize the anaemia of
                        vitamin B
                        <ce:inf>12</ce:inf>
                        deficiency, the neurological sequelae will continue to worsen and may be precipitated.
                        <ce:display>
                            <ce:textbox role="alt1" id="b0010">
                                <ce:textbox-head>
                                    <ce:title>COMMUNICATION</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p0100">Make sure patients are clear that over-the-counter
                                            preparations do not contain sufficient iron for replacement and that
                                            replacement must continue for at least 3 months to replace iron stores.
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                </ce:section>
                <ce:section id="s0050">
                    <ce:section-title id="st0055">Blood transfusion</ce:section-title>
                    <ce:para id="p0105">Blood is given as packed red blood cells (red cell concentrate, RCC) which have
                        been separated from whole blood. In an emergency, where time does not allow cross-matching, O
                        RhD-negative blood can be given safely. Most labs can provide group-matched blood within about
                        30<ce:hsp sp="0.25"/>min; fully cross-matched blood takes longer. Regular blood transfusion may
                        be necessary in chronic anaemia which is not corrected by supplements.
                        <ce:cross-ref refid="f0010">Fig. 37.1</ce:cross-ref>
                        <ce:float-anchor refid="f0010"/>
                        summarizes the complications of transfusion.
                    </ce:para>
                </ce:section>
                <ce:section id="s0055">
                    <ce:section-title id="st0060">Splenectomy</ce:section-title>
                    <ce:para id="p0110">Splenectomy is useful in hereditary spherocytosis and refractory autoimmune
                        haemolytic anaemia. Other indications for splenectomy include trauma, refractory idiopathic
                        thrombocytopenic purpura, and symptomatic splenomegaly (e.g. myelofibrosis, lymphoma and
                        leukaemia). Complications of splenectomy include thrombocytosis and increased susceptibility to
                        infection with encapsulated bacteria (mainly pneumococcus, meningococcus,
                        <ce:italic>Haemophilus influenzae</ce:italic>
                        type B). Patients should be immunized with vaccines against these organisms. Lifelong daily
                        penicillin for prophylaxis is often started post-splenectomy, but this practice may decrease
                        with increasingly resistant bacteria; patients can also be given antibiotics to have on standby
                        in case of fever.
                    </ce:para>
                </ce:section>
                <ce:section id="s0060">
                    <ce:section-title id="st0065">Erythropoietin</ce:section-title>
                    <ce:para id="p0115">Recombinant erythropoietin (EPO) has revolutionized the management of the
                        anaemia associated with chronic renal failure. It is given up to three times a week as
                        subcutaneous or IV injections. Adequate iron stores are needed and it is less effective in
                        inflammatory states. It is also approved for treatment of chemotherapy-induced anaemia in
                        certain situations.
                    </ce:para>
                    <ce:para id="p0120">Complications include hypertension and a rare pure red cell aplasia associated
                        with anti-EPO antibodies. Incidence has decreased with newer agents.
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0065">
                <ce:section-title id="st0070">Causes of anaemia</ce:section-title>
                <ce:para id="p0125">Some specific causes of anaemia are outlined below. For an approach to the diagnosis
                    of anaemia and a more extensive list of causes, see<ce:intra-ref
                            xlink:href="pii:B978-0-7234-3864-9.00029-0" id="ia0020">Ch. 29</ce:intra-ref>.
                </ce:para>
                <ce:section id="s0070">
                    <ce:section-title id="st0075">Anaemia of chronic disease</ce:section-title>
                    <ce:section id="s0075">
                        <ce:section-title id="st0080">Aetiology and pathology</ce:section-title>
                        <ce:para id="p0130">Many chronic diseases, particularly infective, inflammatory or malignant
                            processes, are associated with anaemia. The pathology is multifactorial, with inappropriate
                            utilization of adequate iron stores, reduced erythropoietin production, reduced response to
                            erythropoietin and reduced RBC survival. It has a different pathogenesis and treatment to
                            anaemia seen in chronic renal failure.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0080">
                        <ce:section-title id="st0085">Presentation and complications</ce:section-title>
                        <ce:para id="p0135">Presentation is with the typical symptoms and signs of anaemia, and
                            complications may occur. Signs of the underlying disease may also be present.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0085">
                        <ce:section-title id="st0090">Investigations</ce:section-title>
                        <ce:para id="p0140">Characteristic findings are:
                            <ce:list id="l0015">
                                <ce:list-item id="u0055">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0145">Normochromic normocytic anaemia (may be hypochromic,
                                        microcytic).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0060">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0150">Low serum iron but normal/high serum ferritin.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0065">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0155">Increased iron stores in bone marrow.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0070">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0160">Total iron-binding capacity (TIBC) is low. This helps
                                        differentiate from iron deficiency anaemia (IDA) when TIBC is raised.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0075">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0165">A raised erythrocyte sedimentation rate (ESR), neutrophilia and
                                        thrombocytosis, in addition to the anaemia, constitutes a ‘reactive’ blood
                                        picture reflecting the primary pathology.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                            <ce:display>
                                <ce:textbox role="alt0" id="b0015">
                                    <ce:textbox-head>
                                        <ce:title>HINTS AND TIPS</ce:title>
                                    </ce:textbox-head>
                                    <ce:textbox-body>
                                        <ce:sections>
                                            <ce:para id="p0170">Remember that ferritin is an acute phase protein and may
                                                be misleading in acute illness.
                                            </ce:para>
                                        </ce:sections>
                                    </ce:textbox-body>
                                </ce:textbox>
                            </ce:display>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0090">
                        <ce:section-title id="st0095">Treatment</ce:section-title>
                        <ce:para id="p0175">
                            <ce:list id="l0020">
                                <ce:list-item id="u0080">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0180">Treat the underlying disease.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0085">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0185">If mild and asymptomatic, no treatment is necessary.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0090">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0190">If symptomatic, consider transfusion. EPO is used in rare
                                        cases.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0095">
                    <ce:section-title id="st0100">Haemolytic anaemia</ce:section-title>
                    <ce:para id="p0195">There are many different types of haemolytic anaemia, which may be classified
                        according to whether the disorder is inherited or acquired, and whether the red cell lysis
                        occurs in the peripheral circulation ('intravascular') or in the monocyte-macrophage system –
                        the liver, spleen and lymph nodes ('extravascular'). Abnormalities common to all haemolytic
                        anaemias are as follows:
                        <ce:list id="l0025">
                            <ce:list-item id="u0095">
                                <ce:label>•</ce:label>
                                <ce:para id="p0200">Jaundice due to raised unconjugated bilirubin.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0100">
                                <ce:label>•</ce:label>
                                <ce:para id="p0205">Raised reticulocyte count.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0105">
                                <ce:label>•</ce:label>
                                <ce:para id="p0210">Raised lactate dehydrogenase.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0110">
                                <ce:label>•</ce:label>
                                <ce:para id="p0215">Reduced haptoglobin levels.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                    <ce:para id="p0220">Abnormalities specific to certain causes of haemolytic anaemia are outlined in
                        the sections below. Chronic haemolytic anaemia leads to increased folate requirements, which may
                        not be met, causing a coexistent folate deficiency picture.
                    </ce:para>
                    <ce:section id="s0100">
                        <ce:section-title id="st0105">Glucose-6-phosphate dehydrogenase (G6PD) deficiency
                        </ce:section-title>
                        <ce:para id="p0225">This X-linked recessive condition occurs in around 200 million people
                            worldwide; the most severe form occurs in Mediterraneans. G6PD deficient erythrocytes are
                            susceptible to oxidative stress, which causes haemoglobin to precipitate (Heinz bodies) and
                            haemolysis to occur. In the most common forms the patient is normally asymptomatic, with
                            episodes of acute intravascular and extravascular haemolysis precipitated by infection,
                            drugs or eating fava beans.
                            <ce:list id="l0030">
                                <ce:list-item id="u0115">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0230">There is reduced G6PD concentration and activity. The blood film
                                        in an acute episode shows bite cells, blister cells, Heinz bodies and red cell
                                        fragments.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0120">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0235">Treatment is primarily by avoiding precipitants and treating
                                        underlying causes. Transfusion may be required in acute episodes.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0105">
                        <ce:section-title id="st0110">Pyruvate kinase deficiency</ce:section-title>
                        <ce:para id="p0240">This recessively inherited enzyme deficiency causes a chronic extravascular
                            haemolysis of variable severity, which may be apparent at birth. There is reduced ATP
                            production. In mild disease, the anaemia is often well tolerated due to right shift of the
                            oxygen dissociation curve. Patients may develop complications of chronic haemolysis such as
                            gallstones, hepatosplenomegaly and problems associated with iron overload.
                            <ce:list id="l0035">
                                <ce:list-item id="u0125">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0245">The blood film is often non-specific. Pyruvate kinase activity
                                        is usually low with raised levels of 2,3-diphosphoglycerate.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0130">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0250">Treatment is with transfusion when required; splenectomy is
                                        usually reserved for severe cases.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0110">
                        <ce:section-title id="st0115">Hereditary spherocytosis</ce:section-title>
                        <ce:para id="p0255">This encompasses a number of inherited defects of membrane proteins, most of
                            which are autosomal dominant, causing reduced deformability of RBCs, membrane loss and
                            extravascular destruction. The severity is variable, and around 25% of patients have no
                            anaemia and are not diagnosed until adulthood. However, most patients present in childhood
                            with a mild-to-moderate anaemia, jaundice and splenomegaly. Aplastic crisis can occur in
                            association with viral illness, most commonly parvovirus B19. Complications of long-term
                            haemolysis may develop:
                            <ce:list id="l0040">
                                <ce:list-item id="u0135">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0260">The blood film shows spherocytes and reticulocytes, and bone
                                        marrow examination reveals a compensatory erythroid hyperplasia. The spherocytes
                                        show increased osmotic fragility on testing.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0140">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0265">Splenectomy should be considered on an individual patient basis
                                        taking into account the severity of the anaemia and complications. Folate
                                        supplementation may be required.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0145">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0270">Hereditary elliptocytosis is an autosomal dominant condition
                                        with a similar but milder presentation to that of hereditary spherocytosis.
                                        Blood film shows elliptical RBCs. Most cases require no treatment but the
                                        severity is variable, and severe forms may also require splenectomy and folate
                                        supplementation.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0115">
                        <ce:section-title id="st0120">Sickle cell disease</ce:section-title>
                        <ce:para id="p0275">This is covered below.</ce:para>
                    </ce:section>
                    <ce:section id="s0120">
                        <ce:section-title id="st0125">Autoimmune haemolytic anaemia (AIHA)</ce:section-title>
                        <ce:para id="p0280">In these acquired conditions haemolysis occurs when antibodies bind to the
                            cell surface, either inducing complement-mediated intravascular haemolysis or extravascular
                            destruction. It can be classified according to the temperature at which the antibodies bind:
                            warm AIHA, cold agglutinin disease, or mixed.
                            <ce:list id="l0045">
                                <ce:list-item id="u0150">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0285">Warm AIHA is usually idiopathic but may occur with infection,
                                        other autoimmune disease or malignancy. There is anaemia and jaundice<ce:hsp
                                                sp="0.12"/>±<ce:hsp sp="0.12"/>splenomegaly. In addition to the
                                        non-specific findings, the direct antigen test is positive. Blood film shows
                                        anisocytosis, reticulocytes and spherocytes. Treatment is with steroids;
                                        splenectomy or immunosuppressants are considered if steroids do not control the
                                        haemolysis.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0155">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0290">Cold agglutinin disease is usually due to IgM antibodies,
                                        occurring following infection with
                                        <ce:italic>Mycoplasma pneumoniae</ce:italic>
                                        or infectious mononucleosis, or in association with haematological malignancy.
                                        Complement-mediated haemolysis occurs in the periphery where the temperature is
                                        lower, causing a variable degree of anaemia and peripheral discoloration.
                                        Treatment is by avoiding cold, transfusion, and treating any underlying
                                        condition. When severe, rituximab and plasma exchange may be effective.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0125">
                        <ce:section-title id="st0130">Mechanical haemolytic anaemia</ce:section-title>
                        <ce:para id="p0295">Mechanical destruction ('shearing') of red blood cells can occur in certain
                            diseases or iatrogenically. The most common iatrogenic cause is poorly functioning heart
                            valves; high velocity flow and turbulence across a valve can cause fragmentation of red
                            cells.
                        </ce:para>
                        <ce:para id="p0300">Microangiopathic haemolytic anaemia occurs when widespread activation of the
                            coagulation cascade leads to fibrin strand formation in small vessels, causing shearing of
                            RBCs. This occurs in disseminated intravascular coagulation (DIC), thrombotic
                            thrombocytopenic purpura (TTP), haemolytic uraemic syndrome (HUS) and HELLP syndrome. These
                            are covered later in the chapter.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0130">
                        <ce:section-title id="st0135">Paroxysmal nocturnal haemoglobinuria (PNH)</ce:section-title>
                        <ce:para id="p0305">PNH is an acquired disorder of a haematopoietic precursor cell. An acquired
                            abnormality of a membrane protein renders a proportion of the patient's RBCs vulnerable to
                            lysis by complement. Other cell lines are involved, and the classical triad is of
                            pancytopenia, haemolysis and hypercoagulability.
                        </ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0135">
                    <ce:section-title id="st0140">Sickle cell anaemia</ce:section-title>
                    <ce:para id="p0310">
                        <ce:display>
                            <ce:textbox role="alt0" id="b0020">
                                <ce:textbox-head>
                                    <ce:title>HINTS AND TIPS</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p0315">Do not deny sickle cell patients adequate analgesia during a
                                            crisis through a misplaced fear of drug dependency.
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                    <ce:para id="p0320">Sickle cell anaemia is an inherited (autosomal recessive) condition that most
                        commonly affects Afro-Caribbeans but is also found in the Middle East and Mediterranean. The
                        condition provides advantage in infection with falciparum malaria. It is one cause of sickle
                        cell disease, a term that also encompasses other inherited causes of sickling.
                    </ce:para>
                    <ce:section id="s0140">
                        <ce:section-title id="st0145">Pathology</ce:section-title>
                        <ce:para id="p0325">A single base mutation in the DNA on chromosome 11 causes substitution of
                            glutamic acid for valine at position 6 in the haemoglobin beta chain (HbS). When HbS becomes
                            deoxygenated it aggregates in an organized fashion, forming polymers within the RBCs that
                            are less soluble and less deformable. As a result the erythrocyte shape becomes distorted
                            and changes from a biconcave disc to a ‘sickle’ shape; the sickle cells cannot readily pass
                            through the microcirculation and become trapped in small vessels (causing infarction) and in
                            the spleen, where they are destroyed.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0145">
                        <ce:section-title id="st0150">Clinical features</ce:section-title>
                        <ce:para id="p0330">In the homozygote, severity is variable and dependent on factors such as the
                            level of fetal haemoglobin (HbF) and the co-inheritance of alpha-thalassaemia trait. It may
                            present from the third month onwards when levels of HbF start to fall. There is chronic
                            haemolysis, with intermittent crises and complications. There are four types of sickle cell
                            anaemia crisis:
                            <ce:list id="l0050">
                                <ce:list-item id="u0160">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0335">Aplastic: usually due to parvovirus B19 infection. Profound
                                        anaemia and reticulocytopenia occurs – usually self-limiting but transfusion may
                                        be required.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0165">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0340">Sequestration: sequestration may occur in the spleen or liver.
                                        The haemoglobin drops rapidly, with a compensatory increase in reticulocytes.
                                        The involved organs enlarge rapidly. Splenic sequestration is seen only in
                                        children as the spleen is usually infarcted by the age of 6 years. Exchange
                                        transfusion may be required.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0170">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0345">Painful: due to vascular occlusion. Can be precipitated by
                                        dehydration, hypoxia, infections and cold exposure. Almost any organ can be
                                        affected. Small bones of the hands and feet are most often affected in childhood
                                        (‘hand–foot syndrome’). In older patients, the lungs, hips, shoulders and spine
                                        are more commonly involved. Vascular occlusion is the cause of serious
                                        complications as detailed below.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0175">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0350">Haemolytic: this is rare and may be associated with coexistent
                                        G6PD deficiency. The haemoglobin drops rapidly, with a compensatory increase in
                                        reticulocytes. Increased haemolysis is also seen in association with other
                                        crises.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0150">
                        <ce:section-title id="st0155">Complications</ce:section-title>
                        <ce:para id="p0355">
                            <ce:list id="l0055">
                                <ce:list-item id="u0180">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0360">Anaemia, usually well tolerated.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0185">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0365">Infection: mainly susceptibility to infection with encapsulated
                                        organisms due to hyposplenism (see Splenectomy section), but also infection of
                                        infarcted bone causing osteomyelitis
                                        <ce:italic>(Salmonella</ce:italic>
                                        spp.).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0190">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0370">Vessel occlusion: splenic infarction, TIA and stroke, renal
                                        papillary necrosis, priapism, aseptic necrosis of the femoral head, placental
                                        infarction and spontaneous abortion.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0195">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0375">Gallstones.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0200">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0380">Leg ulceration.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0205">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0385">Acute chest crisis: due to vascular occlusion, infection and
                                        bone marrow embolism. New infiltrates can be seen on X-ray. Mortality is around
                                        3%.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0155">
                        <ce:section-title id="st0160">Investigations</ce:section-title>
                        <ce:para id="p0390">
                            <ce:list id="l0060">
                                <ce:list-item id="u0210">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0395">Normochromic normocytic anaemia, with reticulocytosis, raised
                                        LDH and low haptoglobin.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0215">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0400">Sickle cells, target cells and nucleated RBCs on blood film
                                        (features of hyposplenism may also be present following splenic infarction; see
                                        <ce:intra-ref xlink:href="pii:B978-0-7234-3864-9.00029-0#f0035" id="ia0025">Fig.
                                            29.6</ce:intra-ref>).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0220">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0405">Haemoglobin electrophoresis or chromatography demonstrates HbS.
                                        HbF levels may be raised.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0225">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0410">Leucocyte and platelet counts may also be raised.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0230">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0415">Prenatal diagnosis can be made using polymerase chain reaction
                                        (PCR) techniques on chorionic villous samples.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                        <ce:para id="p0420">The findings are often more severe in episodes of crisis. Other tests may
                            reveal organ-specific complications.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0160">
                        <ce:section-title id="st0165">Treatment</ce:section-title>
                        <ce:para id="p0425">Immunization against encapsulated bacteria and prompt treatment of infection
                            is extremely important. During episodes of crisis, supportive care must include effective
                            analgesia as well as optimization of hydration and oxygenation. Blood transfusion is often
                            necessary. Other treatments include the following:
                            <ce:list id="l0065">
                                <ce:list-item id="u0235">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0430">Hydroxycarbamide (hydroxyurea): this cytotoxic drug is indicated
                                        in patients with painful crises, significant anaemia or other complications. It
                                        increases fetal haemoglobin levels and reduces the frequency of crises. It
                                        causes a macrocytosis and myelosuppression in a dose-dependent manner, and there
                                        may be a risk of leukaemia with long-term treatment.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0240">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0435">Long-term folate (increased folate utilization because of
                                        haemolysis).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0245">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0440">Prophylactic penicillin in children.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0250">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0445">Exchange transfusions if recurrent crises or significant organ
                                        damage.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0255">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0450">Management by a multidisciplinary sickle cell team reduces
                                        admissions and improves patients' quality of life.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                        <ce:para id="p0455">The only curative treatment is haematopoietic cell transplantation, which is
                            only carried out in patients with severe disease who have an HLA-matched sibling. There is
                            ongoing research into gene therapy to increase the expression of HbF.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0165">
                        <ce:section-title id="st0170">Prognosis</ce:section-title>
                        <ce:para id="p0460">There is 5% mortality in the first 10 years of life. Median life expectancy
                            is estimated to be in the mid 50s, with death most commonly due to infection.
                        </ce:para>
                        <ce:para id="p0465">Note that in the sickle cell trait (a heterozygous carrier state) the
                            disease is much milder, with little or no anaemia and a normal blood film. It also provides
                            significant protection against malaria. Crises may be caused in extreme conditions. The most
                            common complication is renal disease.
                        </ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0170">
                    <ce:section-title id="st0175">Thalassaemia</ce:section-title>
                    <ce:para id="p0470">Thalassaemia is an inherited disease of defective haemoglobin production; normal
                        haemoglobin synthesis is summarized in
                        <ce:cross-ref refid="f0015">Fig. 37.2</ce:cross-ref>
                        <ce:float-anchor refid="f0015"/>. The prevalence of thalassaemia is 2.5–15% in affected areas.
                        Alpha-thalassaemia affects those in the Mediterranean, Africa, the Middle East and south-east
                        Asia, whereas beta-thalassaemia is found in China, the Mediterranean, the Middle East and India.
                        It is an inherited condition. The alpha globin gene is on chromosome 16 and the beta gene on
                        chromosome 11.
                    </ce:para>
                    <ce:section id="s0175">
                        <ce:section-title id="st0180">Pathophysiology</ce:section-title>
                        <ce:para id="p0475">
                            <ce:list id="l0070">
                                <ce:list-item id="u0260">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0480">Reduced production of one or more of the haemoglobin chains
                                        (most importantly alpha or beta) results in a relative excess and accumulation
                                        of the other chain (‘imbalanced globin chain synthesis’). There are many known
                                        mutations which result in varying degrees of reduced globin synthesis.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0265">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0485">The unstable haemoglobin precipitates, causing ineffective
                                        erythropoiesis and haemolysis.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0270">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0490">There is deficiency of alpha chains in alpha-thalassaemia and of
                                        beta chains in beta-thalassaemia.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0180">
                        <ce:section-title id="st0185">Clinical features</ce:section-title>
                        <ce:para id="p0495">
                            <ce:list id="l0075">
                                <ce:list-item id="u0275">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0500">The clinical presentation is dependent on the underlying
                                        abnormality, as described in
                                        <ce:cross-ref refid="f0020">Figs 37.3</ce:cross-ref>
                                        <ce:float-anchor refid="f0020"/>
                                        and
                                        <ce:cross-ref refid="f0025">37.4</ce:cross-ref>
                                        <ce:float-anchor refid="f0025"/>. Note that carriers with only one defective
                                        copy of the gene (or two in alpha-thalassaemia) are usually asymptomatic.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0280">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0505">Skeletal change occurs due to expansion of erythropoietic bone
                                        marrow.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0285">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0510">Thalassaemia provides an advantage in infection with falciparum
                                        malaria.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0290">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0515">Aplastic crises may occur with parvovirus B19 infection.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                        <ce:para id="p0520">Microcytic anaemia is the abnormality on a blood film in beta-thalassaemia
                            minor. Differentiation from iron deficiency is possible on the basis of ferritin levels, red
                            cell distribution width (RDW, a measure of homogeneity of red cell size) and clinical
                            suspicion. MCV is usually lower in thalassaemia than IDA.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0185">
                        <ce:section-title id="st0190">Management</ce:section-title>
                        <ce:para id="p0525">
                            <ce:list id="l0080">
                                <ce:list-item id="u0295">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0530">Transfusion to maintain an adequate haemoglobin (&gt;<ce:hsp
                                            sp="0.10"/>10<ce:hsp sp="0.25"/>g/dL) initiated during childhood to ensure
                                        normal growth and development.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0300">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0535">Iron chelation to prevent haemosiderosis using
                                        desferrioxamine.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0305">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0540">Splenectomy can reduce transfusion requirements but should be
                                        avoided where possible because of the increased susceptibility to infection.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0310">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0545">Long-term folate supplementation in severe disease
                                        (beta-thalassaemia major).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0315">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0550">Vitamin D and calcium for skeletal abnormalities.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0320">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0555">Haematopoietic stem cell transplant is an effective treatment
                                        for patients with beta-thalassaemia major, particularly children. However,
                                        HLA-matched cells are not always available.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0325">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0560">Current research emphasis is on the prospect of using gene
                                        therapy techniques.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0330">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0565">Prenatal diagnosis and genetic counselling should be
                                        available.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0190">
                    <ce:section-title id="st0195">Pernicious anaemia</ce:section-title>
                    <ce:para id="p0570">This is an autoimmune condition and has an incidence of roughly 2 per 10<ce:hsp
                            sp="0.15"/>000. However, it is suspected that pernicious anaemia is underdiagnosed and true
                        rates may be much higher, especially in the elderly. There is a strong association with other
                        autoimmune diseases.
                    </ce:para>
                    <ce:section id="s0195">
                        <ce:section-title id="st0200">Pathology</ce:section-title>
                        <ce:para id="p0575">
                            <ce:list id="l0085">
                                <ce:list-item id="u0335">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0580">Immunoglobulin G (IgG) autoantibodies are produced against
                                        gastric parietal cells and intrinsic factor.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0340">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0585">This causes gastric mucosal atrophy with loss of parietal cells
                                        and achlorhydria.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0345">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0590">Production of intrinsic factor, necessary for vitamin B
                                        <ce:inf>12</ce:inf>
                                        absorption, is reduced.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0350">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0595">Binding of vitamin B
                                        <ce:inf>12</ce:inf>
                                        to intrinsic factor is impaired.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0200">
                        <ce:section-title id="st0205">Clinical features</ce:section-title>
                        <ce:para id="p0600">
                            <ce:list id="l0090">
                                <ce:list-item id="u0355">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0605">The onset is usually insidious and is more common after the age
                                        of 50 years.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0360">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0610">Symptoms include those of anaemia and the neurological
                                        complications of vitamin B
                                        <ce:inf>12</ce:inf>
                                        deficiency.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0365">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0615">Examination may reveal anaemia, glossitis, mild jaundice due to
                                        haemolysis, low-grade pyrexia, mild splenomegaly and neurological signs.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0370">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0620">Complications of anaemia (see<ce:intra-ref
                                            xlink:href="pii:B978-0-7234-3864-9.00029-0" id="ia0030">Ch.
                                        29</ce:intra-ref>).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0375">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0625">Neurological abnormalities from vitamin B
                                        <ce:inf>12</ce:inf>
                                        deficiency (peripheral neuropathy, subacute combined degeneration of the cord,
                                        dementia, optic atrophy).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0380">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0630">Increased risk of gastric carcinoma.</ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0205">
                        <ce:section-title id="st0210">Investigations</ce:section-title>
                        <ce:para id="p0635">
                            <ce:list id="l0095">
                                <ce:list-item id="u0385">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0640">Macrocytic anaemia with typical blood film (see<ce:intra-ref
                                            xlink:href="pii:B978-0-7234-3864-9.00029-0#f0035" id="ia0035">Fig.
                                        29.6</ce:intra-ref>).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0390">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0645">White cell and platelet counts: may be low.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0395">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0650">Serum vitamin B<ce:inf>12</ce:inf>: low, with abnormal Schilling
                                        test (now rarely performed).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0400">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0655">Megaloblastic bone marrow: large erythrocytes, large
                                        hypersegmented neutrophils.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0405">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0660">Bilirubin and LDH increased (due to breakdown of abnormal
                                        RBCs).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0410">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0665">Parietal cell antibody in 90% (seen in up to 50% of healthy
                                        elderly).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0415">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0670">Intrinsic factor antibody in 50%.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0420">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0675">Gastroscopy should be considered to exclude gastric carcinoma.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0210">
                        <ce:section-title id="st0215">Treatment</ce:section-title>
                        <ce:para id="p0680">
                            <ce:list id="l0100">
                                <ce:list-item id="u0425">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0685">Lifelong vitamin B
                                        <ce:inf>12</ce:inf>
                                        replacement.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0430">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0690">Initial response to treatment can be demonstrated by an increase
                                        in reticulocyte count.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                        <ce:para id="p0695">Blood transfusion may be required if the patient is haemodynamically
                            compromised or demonstrating ischaemic stress. However, as the patient is often elderly with
                            comorbidities, and the circulation may be hyperdynamic, the risk of precipitating heart
                            failure must be considered. Response to vitamin B
                            <ce:inf>12</ce:inf>
                            is often rapid and transfusion can often be avoided.
                        </ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0215">
                    <ce:section-title id="st0220">Aplastic anaemia</ce:section-title>
                    <ce:para id="p0700">This refers to a condition of pancytopenia, i.e. deficiency of all three marrow
                        cell lines, due to a lack of precursor cells in the bone marrow. It may be congenital or
                        acquired, and is one cause of 'bone marrow failure'. In Caucasians, incidence is around 3 per
                        million per year.
                    </ce:para>
                    <ce:section id="s0220">
                        <ce:section-title id="st0225">Aetiology</ce:section-title>
                        <ce:para id="p0705">Most cases of aplastic anaemia are idiopathic, and it is thought that an
                            autoimmune process is the most likely reason for precursor cell destruction. In a minority
                            of cases of acquired aplastic anaemia there may be a clear link to exposure to viruses,
                            drugs or radiation. The most common form of congenital aplastic anaemia is Fanconi anaemia,
                            a polygenic autosomal recessive or X-linked condition.
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0225">
                        <ce:section-title id="st0230">Clinical features</ce:section-title>
                        <ce:para id="p0710">
                            <ce:list id="l0105">
                                <ce:list-item id="u0435">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0715">Symptoms of anaemia.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0440">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0720">Excess bleeding due to thrombocytopenia.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0445">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0725">Susceptibility to infection due to leucopenia.</ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0230">
                        <ce:section-title id="st0235">Investigations</ce:section-title>
                        <ce:para id="p0730">
                            <ce:list id="l0110">
                                <ce:list-item id="u0450">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0735">Pancytopenia.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0455">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0740">Absence of compensatory reticulocytosis.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0460">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0745">Bone marrow biopsy shows reduced haematopoietic cells and
                                        replacement with fat cells.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0235">
                        <ce:section-title id="st0240">Management</ce:section-title>
                        <ce:para id="p0750">
                            <ce:list id="l0115">
                                <ce:list-item id="u0465">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0755">Supportive measures: platelet and blood transfusion, prompt
                                        treatment of infection.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0470">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0760">Stem cell transplant in younger patients with severe aplastic
                                        anaemia.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0475">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0765">Immune suppression alone in older patients: anti-thymocyte
                                        globulin and ciclosporin are commonly used.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0240">
                    <ce:section-title id="st0245">Sideroblastic anaemia</ce:section-title>
                    <ce:para id="p0770">Sideroblastic anaemia refers to conditions where anaemia is associated with an
                        excess of abnormal sideroblasts: nucleated erythrocyte precursors containing iron granules.
                        There is a defect of haem synthesis, leading to disordered erythropoiesis and excess iron in the
                        marrow.
                    </ce:para>
                    <ce:section id="s0245">
                        <ce:section-title id="st0250">Aetiology</ce:section-title>
                        <ce:para id="p0775">Sideroblastic anaemia can be congenital or acquired:
                            <ce:list id="l0120">
                                <ce:list-item id="u0480">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0780">Congenital: X-linked.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0485">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0785">Acquired: in myelodysplastic syndrome (see below) or secondary
                                        to drugs (e.g. isoniazid, pyrazinamide), alcohol, lead poisoning,
                                        myeloproliferative disease, connective tissue disease.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                        <ce:para id="p0790">The patient presents with symptoms of anaemia.</ce:para>
                    </ce:section>
                    <ce:section id="s0250">
                        <ce:section-title id="st0255">Management</ce:section-title>
                        <ce:para id="p0795">MCV may be low, normal or raised depending on the underlying cause. Ferritin
                            is raised. Bone marrow examination reveals ring sideroblasts, where haem has accumulated
                            into granules that are situated in a perinuclear ring. Treatment is supportive, with blood
                            transfusion, withdrawal of causative agents and iron chelation.
                        </ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0255">
                    <ce:section-title id="st0260">Bone marrow infiltration</ce:section-title>
                    <ce:para id="p0800">Any cause of bone marrow infiltration, if extensive enough, can cause bone
                        marrow failure and anaemia. The causes include proliferative syndromes with fibrosis, amyloid,
                        sarcoidosis lymphoma/leukaemia and metastatic malignancy.
                    </ce:para>
                </ce:section>
                <ce:section id="s0260">
                    <ce:section-title id="st0265">Lead poisoning</ce:section-title>
                    <ce:para id="p0805">This is now rare in developed countries but may occur in adults due to
                        industrial exposure, and in children from inhalation or ingestion of lead-containing products.
                        Presentation may be with gastrointestinal upset, irritability and reduced consciousness, foot
                        drop or wrist drop, and the Burton line on the gums.
                    </ce:para>
                    <ce:para id="p0810">Complications include peripheral neuropathy, encephalopathy, anaemia and
                        nephropathy.
                    </ce:para>
                    <ce:section id="s0265">
                        <ce:section-title id="st0270">Management</ce:section-title>
                        <ce:para id="p0815">
                            <ce:list id="l0125">
                                <ce:list-item id="u0490">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0820">Blood lead levels.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0495">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0825">Full blood count: hypochromic anaemia with basophilic stippling
                                        of RBCs.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0500">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0830">Discuss with poisons information services.</ce:para>
                                </ce:list-item>
                                <ce:list-item id="u0505">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p0835">Treat with disodium calcium edetate (drug of choice), succimer,
                                        dimercaprol or penicillamine.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0270">
            <ce:section-title id="st0275">MYELODYSPLASTIC SYNDROMES</ce:section-title>
            <ce:para id="p0840">These chronic myeloid conditions are classified as neoplastic disorders. They arise from
                acquired mutations in a haematopoietic stem cell, which then develops and proliferates abnormally,
                resulting in an abnormal population of cells in the bone marrow that interferes with normal
                haematopoiesis. There is a risk of transformation into acute leukaemia. They are more common in men and
                in the elderly.
            </ce:para>
            <ce:section id="s0275">
                <ce:section-title id="st0280">Classification</ce:section-title>
                <ce:para id="p0845">MDS is classified according to how many of the cell lines are affected, the
                    proportion of blast cells (early precursor cells) in the marrow, and whether specific chromosomal
                    deletions are present. Sideroblastic anaemia is seen in refractory anaemia with ring sideroblasts
                    (RARS). Risk of leukaemic transformation is highest in refractory anaemia with excess blasts (RAEB).
                    For more information, see Further reading.
                </ce:para>
            </ce:section>
            <ce:section id="s0280">
                <ce:section-title id="st0285">Clinical features</ce:section-title>
                <ce:para id="p0850">The symptoms are non-specific and reflect the underlying deficiency. Patients may
                    present with symptoms due to one or a combination of anaemia, leucopenia and thrombocytopenia.
                </ce:para>
            </ce:section>
            <ce:section id="s0285">
                <ce:section-title id="st0290">Investigations</ce:section-title>
                <ce:para id="p0855">
                    <ce:list id="l0130">
                        <ce:list-item id="u0510">
                            <ce:label>•</ce:label>
                            <ce:para id="p0860">Full blood count: anaemia with low reticulocytes. Thrombocytopenia and
                                leucopenia may be present.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0515">
                            <ce:label>•</ce:label>
                            <ce:para id="p0865">Blood film: poikilocytes (abnormally shaped red cells) and anisocytosis
                                (unequal size).
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0520">
                            <ce:label>•</ce:label>
                            <ce:para id="p0870">Bone marrow exam: hypercellular with abnormal precursors. Ring
                                sideroblasts in RARS. Increased blast cells in RAEB.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0525">
                            <ce:label>•</ce:label>
                            <ce:para id="p0875">Cytogenetics on bone marrow samples may detect underlying chromosomal
                                abnormalities in the clone, which have prognostic implications.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
            </ce:section>
            <ce:section id="s0290">
                <ce:section-title id="st0295">Management</ce:section-title>
                <ce:para id="p0880">A prognostic score should be calculated to help guide treatment. Other factors which
                    are taken into account are the wishes of patients, and their ability to withstand different
                    treatment regimens. Approaches are as follows:
                    <ce:list id="l0135">
                        <ce:list-item id="u0530">
                            <ce:label>•</ce:label>
                            <ce:para id="p0885">Supportive care, including transfusions or red cells and platelets, and
                                prompt treatment of infection.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0535">
                            <ce:label>•</ce:label>
                            <ce:para id="p0890">Low-intensity chemotherapeutic drugs such as azacytadine. These may
                                prolong life but do not offer a cure.
                            </ce:para>
                        </ce:list-item>
                        <ce:list-item id="u0540">
                            <ce:label>•</ce:label>
                            <ce:para id="p0895">High-intensity chemotherapy and stem cell transplant: reserved for
                                younger patients with high-risk disease.
                            </ce:para>
                        </ce:list-item>
                    </ce:list>
                </ce:para>
                <ce:para id="p0900">There are many clinical trials underway investigating the efficacy of different
                    regimens.
                </ce:para>
            </ce:section>
        </ce:section>
        <ce:section id="s0295">
            <ce:section-title id="st0300">LEUKAEMIA</ce:section-title>
            <ce:para id="p0905">The leukaemias are a group of conditions characterized by the malignant proliferation of
                leucocytes in the bone marrow. The cells spill out into the bloodstream and may infiltrate other organs.
            </ce:para>
            <ce:para id="p0910">In the acute leukaemias, there is a proliferation of early lymphoid and myeloid
                precursors (blasts), which do not mature. The clinical course is very aggressive and they are rapidly
                fatal without treatment.
            </ce:para>
            <ce:para id="p0915">The chronic leukaemias have a more indolent course and are characterized by the
                proliferation of lymphoid and myeloid cells that reach maturity (lymphocytes and neutrophils,
                respectively).
            </ce:para>
            <ce:para id="p0920">All leukaemias are best managed by specialists and chemotherapy is a rapidly changing
                field. Most patients are in clinical trials and only the principles need be understood by students and
                junior doctors.
                <ce:display>
                    <ce:textbox role="alt1" id="b0025">
                        <ce:textbox-head>
                            <ce:title>COMMUNICATION</ce:title>
                        </ce:textbox-head>
                        <ce:textbox-body>
                            <ce:sections>
                                <ce:para id="p0925">Leukaemia is a frightening diagnosis for most patients. Make sure
                                    they understand the particular form they have and the outlook with modern therapy.
                                </ce:para>
                            </ce:sections>
                        </ce:textbox-body>
                    </ce:textbox>
                </ce:display>
            </ce:para>
            <ce:section id="s0300">
                <ce:section-title id="st0305">Acute lymphoblastic leukaemia</ce:section-title>
                <ce:section id="s0305">
                    <ce:section-title id="st0310">Epidemiology and aetiology</ce:section-title>
                    <ce:para id="p0930">Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children
                        under 15 years. Only 15% of ALL cases occur in adults. Its aetiology is unknown but is probably
                        multifactorial. A genetic predisposition is suggested by concordance in twins, and the incidence
                        is increased in Down's syndrome and ataxia telangiectasia. The classification of ALL was
                        previously according to the FAB system, but the WHO has recommended moving to classification by
                        underlying cell type (B or T cell) and cytogenetic abnormality.
                    </ce:para>
                </ce:section>
                <ce:section id="s0310">
                    <ce:section-title id="st0315">Pathology</ce:section-title>
                    <ce:para id="p0935">
                        <ce:list id="l0140">
                            <ce:list-item id="u0545">
                                <ce:label>•</ce:label>
                                <ce:para id="p0940">Lymphoblasts proliferate uncontrollably in the bone marrow and cause
                                    bone marrow failure.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0550">
                                <ce:label>•</ce:label>
                                <ce:para id="p0945">Lymphoblasts circulate in the bloodstream and can infiltrate the
                                    lymph nodes, liver, spleen, kidneys, testicles and central nervous system (CNS),
                                    causing organ failure.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0555">
                                <ce:label>•</ce:label>
                                <ce:para id="p0950">The pathological cell is a B-cell precursor in 80% of ALL and a T
                                    cell in the remainder.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0315">
                    <ce:section-title id="st0320">Clinical features</ce:section-title>
                    <ce:para id="p0955">
                        <ce:list id="l0145">
                            <ce:list-item id="u0560">
                                <ce:label>•</ce:label>
                                <ce:para id="p0960">Peaks of incidence are at age 5 years and over 65 years.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0565">
                                <ce:label>•</ce:label>
                                <ce:para id="p0965">The history is usually short, as the disease is so aggressive (days
                                    to a few weeks).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0570">
                                <ce:label>•</ce:label>
                                <ce:para id="p0970">Rapidly proliferating tumour cells in the bone marrow cause bone
                                    pain or symptoms of bone marrow failure (
                                    <ce:cross-ref refid="f0030">Fig. 37.5</ce:cross-ref>
                                    <ce:float-anchor refid="f0030"/>).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0575">
                                <ce:label>•</ce:label>
                                <ce:para id="p0975">There may be fever, lymphadenopathy and hepato- splenomegaly on
                                    examination.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0580">
                                <ce:label>•</ce:label>
                                <ce:para id="p0980">Symptoms or signs due to other organ involvement may be present: for
                                    instance meningism or cranial neuropathies with CNS involvement.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0320">
                    <ce:section-title id="st0325">Investigations</ce:section-title>
                    <ce:para id="p0985">
                        <ce:list id="l0150">
                            <ce:list-item id="u0585">
                                <ce:label>•</ce:label>
                                <ce:para id="p0990">Normochromic normocytic anaemia with low reticulocyte count.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0590">
                                <ce:label>•</ce:label>
                                <ce:para id="p0995">High white cell count due to lymphoblasts; neutropenia may be
                                    present.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0595">
                                <ce:label>•</ce:label>
                                <ce:para id="p1000">Thrombocytopenia.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0600">
                                <ce:label>•</ce:label>
                                <ce:para id="p1005">Bone marrow is hypercellular and dominated by lymphoblasts (usually
                                    &gt;<ce:hsp sp="0.10"/>50%).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0605">
                                <ce:label>•</ce:label>
                                <ce:para id="p1010">Cytogenetic abnormalities may be present (e.g. hyperdiploidy or the
                                    Philadelphia chromosome).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0610">
                                <ce:label>•</ce:label>
                                <ce:para id="p1015">Urate and LDH high.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0615">
                                <ce:label>•</ce:label>
                                <ce:para id="p1020">Mediastinal mass on chest X-ray in T-cell ALL.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0620">
                                <ce:label>•</ce:label>
                                <ce:para id="p1025">Cerebrospinal fluid examination may show lymphoblasts, increased
                                    pressure and increased protein.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0325">
                    <ce:section-title id="st0330">Treatment</ce:section-title>
                    <ce:para id="p1030">All chemotherapy requires careful supportive care with hydration, prophylactic
                        antibiotics, antiviral and antifungal drugs, septic surveillance, blood products to support
                        pancytopenia, bone marrow colony-stimulating factors such as granulocyte colony-stimulating
                        factor, monitoring of coagulation, and allopurinol to prevent tumour lysis syndrome and gout
                        from the increased purine metabolism.
                    </ce:para>
                    <ce:para id="p1035">Treatment should be managed in a specialized unit and include:
                        <ce:list id="l0155">
                            <ce:list-item id="u0625">
                                <ce:label>•</ce:label>
                                <ce:para id="p1040">Cytotoxic chemotherapy in three phases: induction of remission,
                                    consolidation and maintenance. The regimen may be tailored to the cytogenetic
                                    profile: for instance using a tyrosine kinase inhibitor in Philadelphia
                                    chromosome-positive ALL.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0630">
                                <ce:label>•</ce:label>
                                <ce:para id="p1045">CNS prophylaxis: intrathecal methotrexate, cranial irradiation if
                                    high risk.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0635">
                                <ce:label>•</ce:label>
                                <ce:para id="p1050">Monitoring for relapse followed by prompt treatment with salvage
                                    chemotherapy.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0640">
                                <ce:label>•</ce:label>
                                <ce:para id="p1055">Allogeneic bone marrow transplantation often improves outcomes and
                                    can be curative. It is usually reserved for patients with high-risk ALL.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0330">
                    <ce:section-title id="st0335">Prognosis</ce:section-title>
                    <ce:para id="p1060">Prognosis is poor in infants and adults with a 5-year event-free survival of
                        30–40%. In children the 5-year-event-free survival is 70–80%. However, prognosis is very
                        variable and depends upon other factors, including white cell count at presentation, null-cell
                        or T-cell phenotype, male sex and the type of cytogenetic abnormalities.
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0335">
                <ce:section-title id="st0340">Acute myeloid leukaemia</ce:section-title>
                <ce:para id="p1065">AML accounts for 20% of all leukaemias and 80% of adult acute leukaemias. It is much
                    less common in children.
                </ce:para>
                <ce:section id="s0340">
                    <ce:section-title id="st0345">Aetiology</ce:section-title>
                    <ce:para id="p1070">Most cases arise with no clear cause, though many risks are recognized:
                        <ce:list id="l0160">
                            <ce:list-item id="u0645">
                                <ce:label>•</ce:label>
                                <ce:para id="p1075">Ionizing radiation: survivors of Hiroshima.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0650">
                                <ce:label>•</ce:label>
                                <ce:para id="p1080">Chemical exposure: leather and rubber workers (benzene).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0655">
                                <ce:label>•</ce:label>
                                <ce:para id="p1085">Previous chemotherapy: alkylating agents.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0660">
                                <ce:label>•</ce:label>
                                <ce:para id="p1090">Predisposing diseases: myeloproliferative diseases, aplastic anaemia
                                    and myelodysplasia, which can transform to acute leukaemia.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0345">
                    <ce:section-title id="st0350">Pathology</ce:section-title>
                    <ce:para id="p1095">
                        <ce:list id="l0165">
                            <ce:list-item id="u0665">
                                <ce:label>•</ce:label>
                                <ce:para id="p1100">Accumulation of immature haematopoietic blast cells in the bone
                                    marrow, which can cause bone marrow failure.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0670">
                                <ce:label>•</ce:label>
                                <ce:para id="p1105">Blasts can infiltrate the gums, liver, spleen, skin and, less
                                    commonly, the CNS.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0675">
                                <ce:label>•</ce:label>
                                <ce:para id="p1110">AML is traditionally classified as shown in
                                    <ce:cross-ref refid="f0035">Fig. 37.6</ce:cross-ref>
                                    <ce:float-anchor refid="f0035"/>. The more recent WHO classification is shown in
                                    <ce:cross-ref refid="f0040">Fig. 37.7</ce:cross-ref>
                                    <ce:float-anchor refid="f0040"/>.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0350">
                    <ce:section-title id="st0355">Presentation</ce:section-title>
                    <ce:para id="p1115">
                        <ce:list id="l0170">
                            <ce:list-item id="u0680">
                                <ce:label>•</ce:label>
                                <ce:para id="p1120">More frequent with increasing age (median age at presentation is 65
                                    years).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0685">
                                <ce:label>•</ce:label>
                                <ce:para id="p1125">Symptoms are due to marrow failure (<ce:cross-ref refid="f0030">Fig.
                                    37.5</ce:cross-ref>) or organ infiltration by leukaemic cells.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0690">
                                <ce:label>•</ce:label>
                                <ce:para id="p1130">Eye involvement is relatively common.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0695">
                                <ce:label>•</ce:label>
                                <ce:para id="p1135">Bone pain, joint pain and malaise may be prominent symptoms.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0700">
                                <ce:label>•</ce:label>
                                <ce:para id="p1140">Significant hepatomegaly and splenomegaly may occur. Lymphadenopathy
                                    is rare.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0705">
                                <ce:label>•</ce:label>
                                <ce:para id="p1145">Disseminated intravascular coagulation (DIC) has a recognized
                                    association with promyelocytic leukaemia, which carries the t(15:17) translocation
                                    (previously M3).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0710">
                                <ce:label>•</ce:label>
                                <ce:para id="p1150">Gingival hypertrophy and skin lesions are features of monocytic
                                    subtypes M4 and M5.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0715">
                                <ce:label>•</ce:label>
                                <ce:para id="p1155">When the circulating white cell count is very high, leukostasis may
                                    occur, resulting in hyperviscosity symptoms.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0355">
                    <ce:section-title id="st0360">Investigations</ce:section-title>
                    <ce:para id="p1160">
                        <ce:list id="l0175">
                            <ce:list-item id="u0720">
                                <ce:label>•</ce:label>
                                <ce:para id="p1165">Normochromic normocytic anaemia with low reticulocyte count.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0725">
                                <ce:label>•</ce:label>
                                <ce:para id="p1170">High white cell count due to circulating blasts; neutropenia may be
                                    present.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0730">
                                <ce:label>•</ce:label>
                                <ce:para id="p1175">Thrombocytopenia.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0735">
                                <ce:label>•</ce:label>
                                <ce:para id="p1180">Blasts may contain Auer rods (diagnostic of AML).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0740">
                                <ce:label>•</ce:label>
                                <ce:para id="p1185">Bone marrow is hypercellular with blasts constituting at least 20%.
                                    Flow cytometry on the marrow aspirate will help identify the specific cell type.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0745">
                                <ce:label>•</ce:label>
                                <ce:para id="p1190">Cytogenetic abnormalities may be present in around 50% of patients.
                                    For example, an 8:21 translocation is associated with a favourable outcome, whereas
                                    monosomy of chromosome 5 is a poor marker.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0750">
                                <ce:label>•</ce:label>
                                <ce:para id="p1195">Urate and LDH high.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0755">
                                <ce:label>•</ce:label>
                                <ce:para id="p1200">Calcium and phosphate may also be raised.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0760">
                                <ce:label>•</ce:label>
                                <ce:para id="p1205">Abnormal renal or liver function may reflect organ failure due to
                                    infiltration.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0360">
                    <ce:section-title id="st0365">Treatment</ce:section-title>
                    <ce:para id="p1210">Treatment should be managed in a specialized unit. Broad principles are as
                        follows:
                        <ce:list id="l0180">
                            <ce:list-item id="u0765">
                                <ce:label>•</ce:label>
                                <ce:para id="p1215">Supportive care as for all leukaemias (see ALL).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0770">
                                <ce:label>•</ce:label>
                                <ce:para id="p1220">Intensive cytotoxic chemotherapy: induction of remission and
                                    post-remission (consolidation) therapy. The exact regimen is determined by the
                                    subtype and the risk group, and most patients are in a clinical trial.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0775">
                                <ce:label>•</ce:label>
                                <ce:para id="p1225">Bone marrow transplantation following remission may improve outcome
                                    in high-risk patients.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0780">
                                <ce:label>•</ce:label>
                                <ce:para id="p1230">Salvage chemotherapy is required when remission is not achieved or
                                    relapse occurs early.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0785">
                                <ce:label>•</ce:label>
                                <ce:para id="p1235">There are many new agents under investigation, including enzyme
                                    inhibitors and immunotherapeutics such as gemtuzumab.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0790">
                                <ce:label>•</ce:label>
                                <ce:para id="p1240">Monitoring of residual disease is performed with bone marrow
                                    inspection, cytogenetics and molecular techniques such as PCR.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                    <ce:para id="p1245">Treatment of elderly patients is often difficult due to the adverse effects of
                        chemotherapy, and lower-intensity regimens are required.
                    </ce:para>
                </ce:section>
                <ce:section id="s0365">
                    <ce:section-title id="st0370">Prognosis</ce:section-title>
                    <ce:para id="p1250">
                        <ce:list id="l0185">
                            <ce:list-item id="u0795">
                                <ce:label>•</ce:label>
                                <ce:para id="p1255">In most patients, cure/complete remission should be the aim; up to
                                    75% of patients enter remission. Long-term survival is very variable and dependent
                                    on patient-specific factors.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0800">
                                <ce:label>•</ce:label>
                                <ce:para id="p1260">Poor prognostic factors include increasing age, very high white cell
                                    count, secondary leukaemia (e.g. previous myelodysplasia), certain cytogenetic
                                    abnormalities and the presence of DIC.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0370">
                <ce:section-title id="st0375">Chronic lymphocytic leukaemia</ce:section-title>
                <ce:section id="s0375">
                    <ce:section-title id="st0380">Epidemiology and aetiology</ce:section-title>
                    <ce:para id="p1265">Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the
                        developed world (30% of all leukaemias). The incidence increases with age and it is twice as
                        common in males. B-cell CLL and small lymphocytic lymphoma are thought to be part of a spectrum
                        of disease. The aetiology is unknown. Other leukaemias of mature lymphocytes not covered here
                        include hairy cell leukaemia and pro-lymphocytic leukaemias.
                    </ce:para>
                </ce:section>
                <ce:section id="s0380">
                    <ce:section-title id="st0385">Pathology</ce:section-title>
                    <ce:para id="p1270">
                        <ce:list id="l0190">
                            <ce:list-item id="u0805">
                                <ce:label>•</ce:label>
                                <ce:para id="p1275">Proliferation of small lymphocytes in bone marrow, blood and
                                    lymphoid tissues.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0810">
                                <ce:label>•</ce:label>
                                <ce:para id="p1280">These are morphologically mature but functionally abnormal.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0815">
                                <ce:label>•</ce:label>
                                <ce:para id="p1285">95–98% of CLL patients have B-cell phenotype (remainder are T
                                    cells).
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0385">
                    <ce:section-title id="st0390">Clinical features</ce:section-title>
                    <ce:para id="p1290">
                        <ce:list id="l0195">
                            <ce:list-item id="u0820">
                                <ce:label>•</ce:label>
                                <ce:para id="p1295">Some patients are asymptomatic; others may describe malaise, weight
                                    loss, night sweats, recurrent infections, bleeding or symptoms of anaemia.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0825">
                                <ce:label>•</ce:label>
                                <ce:para id="p1300">Lymphadenopathy is usually found (60%).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0830">
                                <ce:label>•</ce:label>
                                <ce:para id="p1305">Hepatosplenomegaly may also be present.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0835">
                                <ce:label>•</ce:label>
                                <ce:para id="p1310">Skin involvement is common.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0390">
                    <ce:section-title id="st0395">Investigations</ce:section-title>
                    <ce:para id="p1315">
                        <ce:list id="l0200">
                            <ce:list-item id="u0840">
                                <ce:label>•</ce:label>
                                <ce:para id="p1320">Monoclonal lymphocytosis with ‘smear’ or ‘smudge’ cells seen on
                                    film.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0845">
                                <ce:label>•</ce:label>
                                <ce:para id="p1325">Anaemia may be due to marrow infiltration or autoimmune haemolysis
                                    (DAT-positive).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0850">
                                <ce:label>•</ce:label>
                                <ce:para id="p1330">Thrombocytopenia may be due to marrow infiltration or autoimmune
                                    destruction.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0855">
                                <ce:label>•</ce:label>
                                <ce:para id="p1335">Bone marrow shows accumulation of mature lymphocytes constituting
                                    over 30% of cells.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0860">
                                <ce:label>•</ce:label>
                                <ce:para id="p1340">Cytogenetic and immunological analysis will offer diagnostic and
                                    prognostic information.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0865">
                                <ce:label>•</ce:label>
                                <ce:para id="p1345">Hypogammaglobulinaemia occurs in 50% and predisposes to infection.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0395">
                    <ce:section-title id="st0400">Treatment</ce:section-title>
                    <ce:para id="p1350">CLL usually follows an indolent course. Staging the disease will help guide
                        treatment. The only potential cure is with stem cell transplant, which carries a high risk of
                        treatment-related mortality. Initially the disease is often asymptomatic, and monitoring is
                        sufficient. When disease becomes symptomatic or rapidly progressive, treatment is indicated.
                        There are ongoing clinical trials.
                        <ce:list id="l0205">
                            <ce:list-item id="u0870">
                                <ce:label>•</ce:label>
                                <ce:para id="p1355">Chlorambucil (an alkylating agent) is an older, established
                                    treatment.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0875">
                                <ce:label>•</ce:label>
                                <ce:para id="p1360">Combination therapy involving fludarabine, cyclophosphamide and
                                    rituximab has shown good results in clinical trials. Other potential agents are
                                    bendamustine and alemtuzumab.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0880">
                                <ce:label>•</ce:label>
                                <ce:para id="p1365">Autoimmune phenomena are responsive to oral prednisolone.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0885">
                                <ce:label>•</ce:label>
                                <ce:para id="p1370">Radiotherapy may be beneficial in symptomatic, localized disease.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0890">
                                <ce:label>•</ce:label>
                                <ce:para id="p1375">Splenectomy is sometimes used in refractory hypersplenism.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0400">
                    <ce:section-title id="st0405">Prognosis</ce:section-title>
                    <ce:para id="p1380">
                        <ce:list id="l0210">
                            <ce:list-item id="u0895">
                                <ce:label>•</ce:label>
                                <ce:para id="p1385">Dependent on extent of disease (survival ranges from 1.5 years to
                                    over 12 years).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0900">
                                <ce:label>•</ce:label>
                                <ce:para id="p1390">In around 10% of CLL, Richter transformation to high-grade lymphoma
                                    occurs as a terminal event.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0405">
                <ce:section-title id="st0410">Chronic myeloid leukaemia</ce:section-title>
                <ce:para id="p1395">CML accounts for 20% of all leukaemias. It can be considered as a myeloproliferative
                    disease. It occurs mainly in middle age, most commonly between 40 and 60 years, with a male
                    preponderance.
                </ce:para>
                <ce:section id="s0410">
                    <ce:section-title id="st0415">Pathology</ce:section-title>
                    <ce:para id="p1400">CML is a malignant proliferation of myeloid cells of unknown aetiology. There is
                        a characteristic chromosome 9:22 reciprocal translocation – the ‘Philadelphia chromosome’. The
                        resulting fusion gene
                        <ce:italic>bcr/abl</ce:italic>
                        possesses elevated tyrosine kinase activity and is believed to be pathogenic in CML.
                    </ce:para>
                </ce:section>
                <ce:section id="s0415">
                    <ce:section-title id="st0420">Clinical features</ce:section-title>
                    <ce:para id="p1405">
                        <ce:list id="l0215">
                            <ce:list-item id="u0905">
                                <ce:label>•</ce:label>
                                <ce:para id="p1410">Symptoms include lethargy, weight loss, sweats and left
                                    hypochondrial discomfort (enlarging spleen).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0910">
                                <ce:label>•</ce:label>
                                <ce:para id="p1415">Symptoms of anaemia or thrombocytopenia may be present.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0915">
                                <ce:label>•</ce:label>
                                <ce:para id="p1420">On examination there is splenomegaly, which may be massive.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0920">
                                <ce:label>•</ce:label>
                                <ce:para id="p1425">Hepatomegaly is present in 50% of cases but lymphadenopathy is
                                    uncommon.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0925">
                                <ce:label>•</ce:label>
                                <ce:para id="p1430">The natural history is characterized by a chronic phase lasting
                                    several years, followed by an acute, aggressive phase similar to acute leukaemia.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0930">
                                <ce:label>•</ce:label>
                                <ce:para id="p1435">Leukostasis may occur with very high leukocyte counts.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0420">
                    <ce:section-title id="st0425">Investigations</ce:section-title>
                    <ce:para id="p1440">
                        <ce:list id="l0220">
                            <ce:list-item id="u0935">
                                <ce:label>•</ce:label>
                                <ce:para id="p1445">Raised white cell count (often very high) with full range of
                                    immature and mature myeloid cells.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0940">
                                <ce:label>•</ce:label>
                                <ce:para id="p1450">Anaemia may be due to marrow infiltration or hypersplenism.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0945">
                                <ce:label>•</ce:label>
                                <ce:para id="p1455">Thrombocytosis is common.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0950">
                                <ce:label>•</ce:label>
                                <ce:para id="p1460">Bone marrow demonstrates accumulation of myeloid cells.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0955">
                                <ce:label>•</ce:label>
                                <ce:para id="p1465">95% of patients have the Philadelphia chromosome on light
                                    microscopy. The other 5% demonstrate the fusion protein through molecular studies.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0960">
                                <ce:label>•</ce:label>
                                <ce:para id="p1470">Neutrophil alkaline phosphatase is low.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0965">
                                <ce:label>•</ce:label>
                                <ce:para id="p1475">Urate and LDH are high.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0970">
                                <ce:label>•</ce:label>
                                <ce:para id="p1480">Serum vitamin B
                                    <ce:inf>12</ce:inf>
                                    is high.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0425">
                    <ce:section-title id="st0430">Treatment</ce:section-title>
                    <ce:para id="p1485">
                        <ce:list id="l0225">
                            <ce:list-item id="u0975">
                                <ce:label>•</ce:label>
                                <ce:para id="p1490">Good supportive therapy as needed.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0980">
                                <ce:label>•</ce:label>
                                <ce:para id="p1495">Imatinib, a specific tyrosine kinase inhibitor (TKI) targeting the
                                    <ce:italic>bcr/abl</ce:italic>
                                    fusion protein, revolutionized treatment of CML. It is well tolerated and produces
                                    clinical and cytogenetic response in the vast majority of cases. Newer TKIs have
                                    been developed and clinical trials are ongoing.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0985">
                                <ce:label>•</ce:label>
                                <ce:para id="p1500">Alpha-interferon and hydroxycarbamide are rarely used and only if
                                    there is intolerance to TKIs.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0990">
                                <ce:label>•</ce:label>
                                <ce:para id="p1505">Allogeneic bone marrow transplantation may be curative and should be
                                    considered in young patients with an HLA-matched sibling and those with blast
                                    crisis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u0995">
                                <ce:label>•</ce:label>
                                <ce:para id="p1510">Leucopheresis will reduce the white count quickly in leukostasis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1000">
                                <ce:label>•</ce:label>
                                <ce:para id="p1515">Frequent monitoring of response to treatment is extremely
                                    important.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0430">
                    <ce:section-title id="st0435">Prognosis</ce:section-title>
                    <ce:para id="p1520">
                        <ce:list id="l0230">
                            <ce:list-item id="u1005">
                                <ce:label>•</ce:label>
                                <ce:para id="p1525">Chronic phase: median time 2–6 years. With TKIs 93% are
                                    progression-free at 6 years.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1010">
                                <ce:label>•</ce:label>
                                <ce:para id="p1530">Acute phase: median survival 3 months without treatment.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1015">
                                <ce:label>•</ce:label>
                                <ce:para id="p1535">Transformation is to AML in two-thirds of patients and to ALL in the
                                    remainder.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0435">
            <ce:section-title id="st0440">MULTIPLE MYELOMA</ce:section-title>
            <ce:para id="p1540">The incidence of multiple myeloma is 5 per 100<ce:hsp sp="0.25"/>000 (1% of all
                malignancies, 10–15% of all haematological malignancies), occurring mainly in the elderly. An abnormal
                proliferation of plasma cells causes features such as a paraprotein, skeletal lesions, bone marrow
                failure, renal impairment and hypercalcaemia.
            </ce:para>
            <ce:para id="p1545">It is one of a number of diseases associated with abnormal proliferation of a clone of
                plasma cells (terminally differentiated B cells), also including:
                <ce:list id="l0235">
                    <ce:list-item id="u1020">
                        <ce:label>•</ce:label>
                        <ce:para id="p1550">Monoclonal gammopathy of uncertain significance (MGUS): presence of a
                            paraprotein but &lt;<ce:hsp sp="0.10"/>5% plasma cells in marrow and no end-organ damage. 1%
                            per year progress to myeloma.
                        </ce:para>
                    </ce:list-item>
                    <ce:list-item id="u1025">
                        <ce:label>•</ce:label>
                        <ce:para id="p1555">Smouldering multiple myeloma: greater than 10% plasma cells in the bone
                            marrow but no end-organ damage (anaemia, hypercalcaemia, renal impairment, bone lesions).
                        </ce:para>
                    </ce:list-item>
                    <ce:list-item id="u1030">
                        <ce:label>•</ce:label>
                        <ce:para id="p1560">Waldenström's macroglobulinaemia: production of large amounts of IgM.
                        </ce:para>
                    </ce:list-item>
                    <ce:list-item id="u1035">
                        <ce:label>•</ce:label>
                        <ce:para id="p1565">Primary systemic amyloidosis: production of light-chain fibrils which are
                            deposited in organs.
                        </ce:para>
                    </ce:list-item>
                </ce:list>
            </ce:para>
            <ce:section id="s0440">
                <ce:section id="s0445">
                    <ce:section-title id="st0445">Pathology</ce:section-title>
                    <ce:para id="p1570">
                        <ce:list id="l0240">
                            <ce:list-item id="u1040">
                                <ce:label>•</ce:label>
                                <ce:para id="p1575">Neoplastic proliferation of a single clone of plasma cells.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1045">
                                <ce:label>•</ce:label>
                                <ce:para id="p1580">The malignant cells secrete a monoclonal immunoglobulin or light
                                    chain and normal immunoglobulin production is suppressed. The plasma cells can form
                                    tumours called plasmacytomas.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1050">
                                <ce:label>•</ce:label>
                                <ce:para id="p1585">Osteoclast activity is increased, resulting in bone reabsorption.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1055">
                                <ce:label>•</ce:label>
                                <ce:para id="p1590">AL (systemic) amyloidosis affects 10% of cases.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0450">
                    <ce:section-title id="st0450">Clinical features</ce:section-title>
                    <ce:para id="p1595">
                        <ce:list id="l0245">
                            <ce:list-item id="u1060">
                                <ce:label>•</ce:label>
                                <ce:para id="p1600">Symptoms of anaemia may be present.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1065">
                                <ce:label>•</ce:label>
                                <ce:para id="p1605">Bone pain due to osteolytic lesions and pathological fractures
                                    affect two-thirds of patients.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1070">
                                <ce:label>•</ce:label>
                                <ce:para id="p1610">Hypercalcaemia is often present, causing typical symptoms (see
                                    <ce:intra-ref xlink:href="pii:B978-0-7234-3864-9.00035-6" id="ia0040">Ch.
                                        35</ce:intra-ref>).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1075">
                                <ce:label>•</ce:label>
                                <ce:para id="p1615">Renal impairment: often due to light-chain deposition or
                                    hypercalcaemia.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1080">
                                <ce:label>•</ce:label>
                                <ce:para id="p1620">Recurrent infections result from impaired antibody response and
                                    hypogammaglobulinaemia.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1085">
                                <ce:label>•</ce:label>
                                <ce:para id="p1625">Examination usually reveals pallor alone.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1090">
                                <ce:label>•</ce:label>
                                <ce:para id="p1630">Spinal cord compression and radiculopathy can result from
                                    compression by tumour or vertebral collapse.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1095">
                                <ce:label>•</ce:label>
                                <ce:para id="p1635">Polymerization of the monoclonal antibody occasionally results in
                                    hyperviscosity syndrome.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0455">
                    <ce:section-title id="st0455">Investigations</ce:section-title>
                    <ce:para id="p1640">
                        <ce:list id="l0250">
                            <ce:list-item id="u1100">
                                <ce:label>•</ce:label>
                                <ce:para id="p1645">Normochromic normocytic anaemia.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1105">
                                <ce:label>•</ce:label>
                                <ce:para id="p1650">Rouleaux (RBCs sticking together) and background immunoglobulin
                                    staining may be seen on the blood film.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1110">
                                <ce:label>•</ce:label>
                                <ce:para id="p1655">Plasma viscosity and ESR: usually high.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1115">
                                <ce:label>•</ce:label>
                                <ce:para id="p1660">Serum protein electrophoresis demonstrates a monoclonal paraprotein.
                                    In 60% it is IgG, 25% IgA. Free light chains are not usually detected with this
                                    method. Quantification and serial measurement of the paraprotein enables effective
                                    monitoring.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1120">
                                <ce:label>•</ce:label>
                                <ce:para id="p1665">Free light chains may be detected in the urine ('Bence Jones
                                    protein') with urine electrophoresis, or in the serum with a serum free light-chain
                                    assay. The majority of paraprotein-negative myeloma secrete free light chains; a
                                    small number are truly non-secretory.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1125">
                                <ce:label>•</ce:label>
                                <ce:para id="p1670">Skeletal survey with X-rays reveals generalized osteopenia,
                                    ‘punched-out’ lytic lesions (‘pepperpot skull’) and pathological fractures. Bone
                                    scans are not helpful.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1130">
                                <ce:label>•</ce:label>
                                <ce:para id="p1675">Bone marrow aspirate shows that over 10% of bone marrow cells are
                                    plasma cells. Cytogenetic analysis is increasingly helpful for prognosis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1135">
                                <ce:label>•</ce:label>
                                <ce:para id="p1680">Calcium high; alkaline phosphatase usually normal.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1140">
                                <ce:label>•</ce:label>
                                <ce:para id="p1685">Renal failure may result from a number of factors (
                                    <ce:cross-ref refid="f0045">Fig. 37.8</ce:cross-ref>
                                    <ce:float-anchor refid="f0045"/>).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1145">
                                <ce:label>•</ce:label>
                                <ce:para id="p1690">Beta-2-microglobulin level usually high.</ce:para>
                            </ce:list-item>
                        </ce:list>
                        <ce:display>
                            <ce:textbox role="alt0" id="b0030">
                                <ce:textbox-head>
                                    <ce:title>HINTS AND TIPS</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p1695">Psychological care of very sick or terminally ill patients
                                            is an important part of their management, and referral to a clinical
                                            psychologist may help patients cope with their illness.
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                </ce:section>
                <ce:section id="s0460">
                    <ce:section-title id="st0460">Treatment</ce:section-title>
                    <ce:para id="p1700">
                        <ce:list id="l0255">
                            <ce:list-item id="u1150">
                                <ce:label>•</ce:label>
                                <ce:para id="p1705">Monitoring only in MGUS and smouldering myeloma.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1155">
                                <ce:label>•</ce:label>
                                <ce:para id="p1710">Supportive treatment with antibiotics, blood products, analgesics
                                    and correction of hypercalcaemia where necessary.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1160">
                                <ce:label>•</ce:label>
                                <ce:para id="p1715">Autologous stem cell transplant (ASCT) improves event-free survival
                                    (though is not curative) and is performed when the patient is healthy enough to
                                    undergo the high-dose chemotherapy required.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1165">
                                <ce:label>•</ce:label>
                                <ce:para id="p1720">Prior to ASCT, chemotherapy is required to induce remission. There
                                    are several potential regimens, such as CTD (cyclophosphamide, thalidomide,
                                    dexamethasone). Newer agents such as bortezomib are effective.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1170">
                                <ce:label>•</ce:label>
                                <ce:para id="p1725">In patients not eligible for ASCT, induction chemotherapy regimens
                                    may be modified to minimize toxicity.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1175">
                                <ce:label>•</ce:label>
                                <ce:para id="p1730">There may be a role for maintenance therapy after ASCT or induction
                                    chemotherapy.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1180">
                                <ce:label>•</ce:label>
                                <ce:para id="p1735">Following relapse, the treatment depends on the individual case.
                                    Further induction chemotherapy may be used, and there may be a role for a second
                                    ASCT. In those not able to tolerate the above, lenalidomide offers improved
                                    survival.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1185">
                                <ce:label>•</ce:label>
                                <ce:para id="p1740">Allogeneic transplantation may be curative but has a high mortality.
                                    It is an option for younger patients, after proper discussion of the risks.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1190">
                                <ce:label>•</ce:label>
                                <ce:para id="p1745">Radiotherapy may be useful where there is localized disease causing
                                    bony pain.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                        Please see Further reading for more details.
                    </ce:para>
                </ce:section>
                <ce:section id="s0465">
                    <ce:section-title id="st0465">Prognosis</ce:section-title>
                    <ce:para id="p1755">
                        <ce:list id="l0260">
                            <ce:list-item id="u1195">
                                <ce:label>•</ce:label>
                                <ce:para id="p1760">The prognosis is very variable. Median survival is roughly 4
                                    years.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1200">
                                <ce:label>•</ce:label>
                                <ce:para id="p1765">Poor prognostic factors include certain cytogenetic profiles, high
                                    beta-2-microglobulin levels (most accurate), high paraprotein levels, high urea, low
                                    haemoglobin, increasing age and low albumin.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0470">
            <ce:section-title id="st0470">LYMPHOMA</ce:section-title>
            <ce:para id="p1770">Lymphomas are neoplastic proliferations of lymphocytes that form solid tumours within
                lymphoid tissue. They are split into two broad categories on the basis of histological findings:
                Hodgkin's disease (Reed–Sternberg (RS) cells present) and non-Hodgkin's lymphoma (all others).
            </ce:para>
            <ce:section id="s0475">
                <ce:section-title id="st0475">Hodgkin's disease</ce:section-title>
                <ce:section id="s0480">
                    <ce:section-title id="st0480">Incidence and aetiology</ce:section-title>
                    <ce:para id="p1775">The incidence of Hodgkin's disease is 5 in 100<ce:hsp sp="0.25"/>000; it is one
                        of the most common malignancies in young adults and accounts for around 10–15% of all lymphomas.
                        There is a bimodal age distribution with peaks at 20–30 years and above 50 years with a male
                        preponderance in childhood Hodgkin's disease. Its aetiology is unknown but there is a link with
                        Epstein–Barr virus (EBV) and an increased risk in immunodeficient states (e.g. HIV,
                        immunosuppressant therapy). It mainly affects Caucasian populations and is more common in higher
                        socioeconomic groups.
                    </ce:para>
                </ce:section>
                <ce:section id="s0485">
                    <ce:section-title id="st0485">Pathology</ce:section-title>
                    <ce:para id="p1780">
                        <ce:list id="l0265">
                            <ce:list-item id="u1205">
                                <ce:label>•</ce:label>
                                <ce:para id="p1785">Characteristic RS cells in a background of inflammatory
                                    infiltrate.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1210">
                                <ce:label>•</ce:label>
                                <ce:para id="p1790">RS cells are large bi- or multinuclear cells with prominent
                                    ‘owl-eyed’ nucleoli.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1215">
                                <ce:label>•</ce:label>
                                <ce:para id="p1795">Hodgkin's disease is divided, using the Rye classification, into
                                    five histological subgroups (
                                    <ce:cross-ref refid="f0050">Fig. 37.9</ce:cross-ref>
                                    <ce:float-anchor refid="f0050"/>).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1220">
                                <ce:label>•</ce:label>
                                <ce:para id="p1800">The pathological cell in nodular lymphocyte-predominant Hodgkin's
                                    disease is a variant of the RS cell, sometimes termed the 'popcorn cell'.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0490">
                    <ce:section-title id="st0490">Clinical features</ce:section-title>
                    <ce:para id="p1805">
                        <ce:list id="l0270">
                            <ce:list-item id="u1225">
                                <ce:label>•</ce:label>
                                <ce:para id="p1810">Symptoms are due to painless lymph node enlargement (particularly
                                    cervical, axillary and mediastinal) and/or ‘B symptoms’ (
                                    <ce:cross-ref refid="f0055">Fig. 37.10</ce:cross-ref>
                                    <ce:float-anchor refid="f0055"/>).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1230">
                                <ce:label>•</ce:label>
                                <ce:para id="p1815">Lymphadenopathy is supradiaphragmatic in 90% of patients and
                                    mediastinal disease may cause dry cough and exertional dyspnoea.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1235">
                                <ce:label>•</ce:label>
                                <ce:para id="p1820">Affected lymph nodes feel rubbery and are non-tender.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1240">
                                <ce:label>•</ce:label>
                                <ce:para id="p1825">Some patients describe pruritus and alcohol-induced lymph node
                                    pain.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1245">
                                <ce:label>•</ce:label>
                                <ce:para id="p1830">Pallor and hepatosplenomegaly may also be found on examination.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0495">
                    <ce:section-title id="st0495">Investigations</ce:section-title>
                    <ce:para id="p1835">
                        <ce:list id="l0275">
                            <ce:list-item id="u1250">
                                <ce:label>•</ce:label>
                                <ce:para id="p1840">Diagnosis requires lymph node biopsy, and excision of a whole node
                                    is performed if possible to provide adequate structural information. Needle
                                    aspiration is insufficient.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1255">
                                <ce:label>•</ce:label>
                                <ce:para id="p1845">Staging of disease is then performed with whole-body CT or PET-CT (
                                    <ce:cross-ref refid="f0060">Fig. 37.11</ce:cross-ref>
                                    <ce:float-anchor refid="f0060"/>).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1260">
                                <ce:label>•</ce:label>
                                <ce:para id="p1850">Bone marrow examination is usually required for staging, especially
                                    if B symptoms are prominent. Reed–Sternberg cells in the bone marrow indicates stage
                                    IV disease.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1265">
                                <ce:label>•</ce:label>
                                <ce:para id="p1855">Normochromic normocytic anaemia, neutrophilia, eosinophilia and
                                    thrombocytosis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1270">
                                <ce:label>•</ce:label>
                                <ce:para id="p1860">Alkaline phosphatase may be raised.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1275">
                                <ce:label>•</ce:label>
                                <ce:para id="p1865">LDH raised in bulky disease (prognostic indicator and marker of
                                    disease activity).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1280">
                                <ce:label>•</ce:label>
                                <ce:para id="p1870">Urate high in bulky disease.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1285">
                                <ce:label>•</ce:label>
                                <ce:para id="p1875">ESR and CRP often raised.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1290">
                                <ce:label>•</ce:label>
                                <ce:para id="p1880">Chest X-ray: mediastinal lymphadenopathy</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1295">
                                <ce:label>•</ce:label>
                                <ce:para id="p1885">Staging laparotomy or splenic biopsy is very rarely performed when
                                    the diagnosis is suspected but there is no other accessible pathological tissue.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0500">
                    <ce:section-title id="st0500">Treatment</ce:section-title>
                    <ce:para id="p1890">
                        <ce:list id="l0280">
                            <ce:list-item id="u1300">
                                <ce:label>•</ce:label>
                                <ce:para id="p1895">Early disease (stages I–II) without adverse prognostic factors (see
                                    below) is treated with up to four cycles of ABVD (Adriamycin (doxorubicin),
                                    bleomycin, vinblastine, dacarbazine) chemotherapy and radiotherapy.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1305">
                                <ce:label>•</ce:label>
                                <ce:para id="p1900">Early disease with adverse prognostic factors is treated with longer
                                    courses of chemotherapy (tailored to response as measured by PET scan) and
                                    radiotherapy.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1310">
                                <ce:label>•</ce:label>
                                <ce:para id="p1905">Extensive disease (stage III–IV) is treated with chemotherapy alone.
                                    ABVD is the accepted standard. Other regimens are BEACOPP and Stanford V.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1315">
                                <ce:label>•</ce:label>
                                <ce:para id="p1910">Relapse is treated with alternative chemotherapy regimen or
                                    high-dose chemotherapy followed by autologous haematopoietic stem cell transplant.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0505">
                    <ce:section-title id="st0505">Prognosis</ce:section-title>
                    <ce:para id="p1915">The outlook for the predominantly young patients is good and a positive outcome
                        should be expected.
                        <ce:list id="l0285">
                            <ce:list-item id="u1320">
                                <ce:label>•</ce:label>
                                <ce:para id="p1920">Prognosis is greatly affected by histological type and stage of
                                    disease at presentation. With treatment, early disease without adverse factors has
                                    10-year survival of up to 97%. Even advanced disease has 5-year survival rates of
                                    over 50%.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1325">
                                <ce:label>•</ce:label>
                                <ce:para id="p1925">Poor prognostic indicators include B symptoms, high-stage,
                                    lymphocyte-depleted histology, increasing age, bulky mediastinal disease, high ESR
                                    and low albumin.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0510">
                <ce:section-title id="st0510">Non-Hodgkin's lymphoma</ce:section-title>
                <ce:section id="s0515">
                    <ce:section-title id="st0515">Incidence and aetiology</ce:section-title>
                    <ce:para id="p1930">Non-Hodgkin's lymphoma (NHL) accounts for over 3% of all cancer-related deaths.
                        Incidence increases with age and the condition is more common in males. The aetiology is
                        multifactorial, including:
                        <ce:list id="l0290">
                            <ce:list-item id="u1330">
                                <ce:label>•</ce:label>
                                <ce:para id="p1935">Genetic predisposition.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1335">
                                <ce:label>•</ce:label>
                                <ce:para id="p1940">Immunosuppression (particularly human immunodeficiency virus (HIV)
                                    infection, also transplant recipients).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1340">
                                <ce:label>•</ce:label>
                                <ce:para id="p1945">Viruses (e.g. EBV, particularly Burkitt's lymphoma).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1345">
                                <ce:label>•</ce:label>
                                <ce:para id="p1950">A possible link with exposure to ionizing radiation.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0520">
                    <ce:section-title id="st0520">Pathology</ce:section-title>
                    <ce:para id="p1955">
                        <ce:list id="l0295">
                            <ce:list-item id="u1350">
                                <ce:label>•</ce:label>
                                <ce:para id="p1960">Highly heterogeneous group of conditions in terms of pathological
                                    cell type and clinical course.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1355">
                                <ce:label>•</ce:label>
                                <ce:para id="p1965">Neoplastic proliferation of B (usually) or T lymphocytes within the
                                    lymphoid system forming solid tumours which do not have RS cells.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1360">
                                <ce:label>•</ce:label>
                                <ce:para id="p1970">The most commonly used classification is the WHO classification,
                                    which was updated in 2008, and classifies neoplasms by the cell of origin.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1365">
                                <ce:label>•</ce:label>
                                <ce:para id="p1975">In practical terms it is often useful to classify lymphomas as
                                    indolent/low grade or aggressive/high grade although disease behaviour varies
                                    greatly between individuals, and transformation frequently occurs.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0525">
                    <ce:section-title id="st0525">Clinical features</ce:section-title>
                    <ce:para id="p1980">
                        <ce:list id="l0300">
                            <ce:list-item id="u1370">
                                <ce:label>•</ce:label>
                                <ce:para id="p1985">Indolent lymphoma (such as most follicular lymphomas) usually
                                    presents with slowly enlarging lymphadenopathy and less commonly with B symptoms.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1375">
                                <ce:label>•</ce:label>
                                <ce:para id="p1990">Aggressive lymphoma (such as lymphoblastic, diffuse large B-cell or
                                    Burkitt's lymphoma) may present with a rapidly growing mass and commonly with B
                                    symptoms.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1380">
                                <ce:label>•</ce:label>
                                <ce:para id="p1995">A great number of symptoms and signs may be present due to
                                    involvement of extranodal sites including skin, lung, bowel, CNS and bone.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1385">
                                <ce:label>•</ce:label>
                                <ce:para id="p2000">Low-grade NHL progresses slowly but cure is unlikely; high-grade NHL
                                    causes death within months if untreated, but may be cured in up to 40% of patients.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1390">
                                <ce:label>•</ce:label>
                                <ce:para id="p2005">Lymphadenopathy, hepatosplenomegaly, pallor and involvement of
                                    extranodal sites should be looked for on examination.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0530">
                    <ce:section-title id="st0530">Investigations</ce:section-title>
                    <ce:para id="p2010">
                        <ce:list id="l0305">
                            <ce:list-item id="u1395">
                                <ce:label>•</ce:label>
                                <ce:para id="p2015">Lymph node biopsy for histology, immunohistochemistry and
                                    cytogenetics.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1400">
                                <ce:label>•</ce:label>
                                <ce:para id="p2020">Staging should then be performed to determine the extent of disease
                                    using the Ann Arbor system (<ce:cross-ref refid="f0060">Fig. 37.11</ce:cross-ref>).
                                    This usually comprises CT or PET scan and bone marrow biopsy.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1405">
                                <ce:label>•</ce:label>
                                <ce:para id="p2025">Circulating lymphoma cells are sometimes seen on the peripheral
                                    film.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1410">
                                <ce:label>•</ce:label>
                                <ce:para id="p2030">Full blood count may show evidence of bone marrow failure if
                                    extensively infiltrated.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1415">
                                <ce:label>•</ce:label>
                                <ce:para id="p2035">LDH and urate may be high in bulky disease.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1420">
                                <ce:label>•</ce:label>
                                <ce:para id="p2040">Paraproteinaemia and immune paresis (reduction in normal
                                    immunoglobulins) may be found.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1425">
                                <ce:label>•</ce:label>
                                <ce:para id="p2045">Lumbar puncture if there is any suspicion of CNS involvement. The
                                    CSF should be sent for cytology or flow cytometry.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0535">
                    <ce:section-title id="st0535">Treatment</ce:section-title>
                    <ce:section id="s0540">
                        <ce:section-title id="st0540">Indolent NHL</ce:section-title>
                        <ce:para id="p2050">Follicular lymphoma is the most common subtype.
                            <ce:list id="l0310">
                                <ce:list-item id="u1430">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p2055">Stage I or II disease: radiotherapy offers a small chance of
                                        cure. Observation is reasonable if radiotherapy would cause significant
                                        morbidity.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u1435">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p2060">Stage III or IV: observation if asymptomatic. In symptomatic
                                        disease, rituximab is given with combination chemotherapy. After successful
                                        induction therapy, rituximab is given as maintenance treatment.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u1440">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p2065">Combination chemotherapy<ce:hsp sp="0.12"/>±<ce:hsp sp="0.12"/>
                                        rituximab can be given in refractory disease. There is also a role for
                                        autologous stem cell transplant.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                    </ce:section>
                    <ce:section id="s0545">
                        <ce:section-title id="st0545">Aggressive NHL</ce:section-title>
                        <ce:para id="p2070">Diffuse large B-cell lymphoma is the most common subtype.
                            <ce:list id="l0315">
                                <ce:list-item id="u1445">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p2075">Limited stage I or II disease: radiotherapy, rituximab
                                        (monoclonal anti-CD20) and short-course chemotherapy. CHOP (cyclophosphamide,
                                        hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), prednisolone) is the
                                        gold standard.
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u1450">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p2080">In stage III and IV disease, or bulky early-stage disease,
                                        treatment is rituximab and longer courses of chemotherapy(usually 6–8 cycles).
                                    </ce:para>
                                </ce:list-item>
                                <ce:list-item id="u1455">
                                    <ce:label>•</ce:label>
                                    <ce:para id="p2085">Relapsed or refractory disease is treated with alternative
                                        chemotherapy with the aim of proceeding to stem cell transplant in eligible
                                        patients.
                                    </ce:para>
                                </ce:list-item>
                            </ce:list>
                        </ce:para>
                        <ce:para id="p2090">Rituximab is not used in T-cell lymphoma.</ce:para>
                    </ce:section>
                </ce:section>
                <ce:section id="s0550">
                    <ce:section-title id="st0550">Prognosis</ce:section-title>
                    <ce:para id="p2095">
                        <ce:list id="l0320">
                            <ce:list-item id="u1460">
                                <ce:label>•</ce:label>
                                <ce:para id="p2100">Low-grade NHL: median survival is around 8–10 years.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1465">
                                <ce:label>•</ce:label>
                                <ce:para id="p2105">High-grade NHL: 40% 5-year disease-free survival.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1470">
                                <ce:label>•</ce:label>
                                <ce:para id="p2110">Poor prognostic factors include increasing age, high LDH, extensive
                                    disease, T-cell phenotype, certain extranodal sites, poor performance status and
                                    low-grade NHL that has transformed into high-grade NHL.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0555">
            <ce:section-title id="st0555">MYELOPROLIFERATIVE DISEASE</ce:section-title>
            <ce:para id="p2115">These conditions, like myelodysplastic syndromes (MDS), are chronic myeloid neoplasms
                caused by proliferation of a myeloid precursor cell. The abnormal cells differentiate into mature cells
                and, in contrast to MDS, evidence of this is seen in the peripheral blood. There are four classical
                syndromes: chronic myeloid leukaemia (associated with the Philadelphia chromosome and covered above),
                essential thrombocythaemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF). An acquired
                mutation of
                <ce:italic>JAK2</ce:italic>
                is present in around 95% of patients with PV and up to 60% of patients with ET or PMF.
            </ce:para>
            <ce:section id="s0560">
                <ce:section-title id="st0560">Polycythaemia vera</ce:section-title>
                <ce:para id="p2120">In PV there is an increased number of circulating erythrocytes (raised haematocrit)
                    which cannot be ascribed to other causes (e.g. chronic hypoxia). There is a risk of developing
                    myelofibrosis or transformation to acute leukaemia.
                </ce:para>
                <ce:section id="s0565">
                    <ce:section-title id="st0565">Clinical features</ce:section-title>
                    <ce:para id="p2125">
                        <ce:list id="l0325">
                            <ce:list-item id="u1475">
                                <ce:label>•</ce:label>
                                <ce:para id="p2130">Symptoms of raised haematocrit include headache, weakness, sweating
                                    and dizziness.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1480">
                                <ce:label>•</ce:label>
                                <ce:para id="p2135">Arthralgia and pruritus are commonly experienced.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1485">
                                <ce:label>•</ce:label>
                                <ce:para id="p2140">Thrombosis may cause visual disturbance.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1490">
                                <ce:label>•</ce:label>
                                <ce:para id="p2145">The patient looks plethoric (red complexion) and splenomegaly is
                                    present.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0570">
                    <ce:section-title id="st0570">Investigations</ce:section-title>
                    <ce:para id="p2150">
                        <ce:list id="l0330">
                            <ce:list-item id="u1495">
                                <ce:label>•</ce:label>
                                <ce:para id="p2155">Full blood count: raised haematocrit. Thrombocytosis and
                                    leucocytosis in 50%.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1500">
                                <ce:label>•</ce:label>
                                <ce:para id="p2160">Arterial blood gas and erythropoietin level help exclude secondary
                                    polycythaemia.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1505">
                                <ce:label>•</ce:label>
                                <ce:para id="p2165">
                                    <ce:italic>JAK2</ce:italic>
                                    mutation analysis on peripheral blood.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1510">
                                <ce:label>•</ce:label>
                                <ce:para id="p2170">Bone marrow examination may be required if there is doubt about the
                                    diagnosis or concern about transformation. There is hypercellularity with reduced
                                    iron stores.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0575">
                    <ce:section-title id="st0575">Treatment</ce:section-title>
                    <ce:para id="p2175">
                        <ce:list id="l0335">
                            <ce:list-item id="u1515">
                                <ce:label>•</ce:label>
                                <ce:para id="p2180">In simple erythrocytosis: venesection to lower the haematocrit.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1520">
                                <ce:label>•</ce:label>
                                <ce:para id="p2185">If coexistent thrombocytosis or thrombotic events: hydroxyurea.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0580">
                <ce:section-title id="st0580">Essential thrombocythaemia</ce:section-title>
                <ce:para id="p2190">In essential thrombocythaemia (ET), the platelet count is markedly elevated and the
                    platelets are functionally abnormal. Life expectancy is usually normal with treatment.
                </ce:para>
                <ce:section id="s0585">
                    <ce:section-title id="st0585">Clinical features</ce:section-title>
                    <ce:para id="p2195">
                        <ce:list id="l0340">
                            <ce:list-item id="u1525">
                                <ce:label>•</ce:label>
                                <ce:para id="p2200">The majority of patients are asymptomatic at the time of
                                    diagnosis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1530">
                                <ce:label>•</ce:label>
                                <ce:para id="p2205">Patients may report headache, lightheadedness or syncope.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1535">
                                <ce:label>•</ce:label>
                                <ce:para id="p2210">Episodes of thrombosis and/or bleeding may occur.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1540">
                                <ce:label>•</ce:label>
                                <ce:para id="p2215">Transformation to PV, acute leukaemia or myelofibrosis may occur.
                                    Most commonly the condition evolves to myelofibrosis (5–10% at 10 years).
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0590">
                    <ce:section-title id="st0590">Investigations</ce:section-title>
                    <ce:para id="p2220">
                        <ce:list id="l0345">
                            <ce:list-item id="u1545">
                                <ce:label>•</ce:label>
                                <ce:para id="p2225">Causes of a reactive thrombocytosis must be excluded.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1550">
                                <ce:label>•</ce:label>
                                <ce:para id="p2230">Full blood count shows elevated platelets &gt;<ce:hsp sp="0.10"/>600
                                    on two separate occasions.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1555">
                                <ce:label>•</ce:label>
                                <ce:para id="p2235">Blood film may show bizarre-looking platelets and platelet
                                    aggregates.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1560">
                                <ce:label>•</ce:label>
                                <ce:para id="p2240">Bone marrow examination: hypercellularity, abundant megakaryocytes
                                    without significant fibrosis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1565">
                                <ce:label>•</ce:label>
                                <ce:para id="p2245">
                                    <ce:italic>JAK2</ce:italic>
                                    mutation present in around 60%.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0595">
                    <ce:section-title id="st0595">Treatment</ce:section-title>
                    <ce:para id="p2250">
                        <ce:list id="l0350">
                            <ce:list-item id="u1570">
                                <ce:label>•</ce:label>
                                <ce:para id="p2255">Observation alone is sufficient in young patients at low risk of
                                    thrombosis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1575">
                                <ce:label>•</ce:label>
                                <ce:para id="p2260">Aspirin is useful for mild symptoms in low-risk patients.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1580">
                                <ce:label>•</ce:label>
                                <ce:para id="p2265">Platelet-lowering therapy is required for patients at high risk of
                                    thrombosis; hydroxyurea and anagrelide are both effective.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0600">
                <ce:section-title id="st0600">Primary myelofibrosis</ce:section-title>
                <ce:para id="p2270">In primary myelofibrosis (PMF), there is proliferation of abnormal cells in all
                    three cell lines, accompanied by release of growth factors which cause bone marrow fibrosis.
                </ce:para>
                <ce:section id="s0605">
                    <ce:section-title id="st0605">Clinical features</ce:section-title>
                    <ce:para id="p2275">
                        <ce:list id="l0355">
                            <ce:list-item id="u1585">
                                <ce:label>•</ce:label>
                                <ce:para id="p2280">Systemic symptoms: fatigue, weight loss, night sweats.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1590">
                                <ce:label>•</ce:label>
                                <ce:para id="p2285">Extramedullary haematopoiesis leads to massive splenomegaly, which
                                    may cause discomfort or early satiety. Hepatomegaly is often present.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1595">
                                <ce:label>•</ce:label>
                                <ce:para id="p2290">There is an increased risk of thrombotic events.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0610">
                    <ce:section-title id="st0610">Investigations</ce:section-title>
                    <ce:para id="p2295">
                        <ce:list id="l0360">
                            <ce:list-item id="u1600">
                                <ce:label>•</ce:label>
                                <ce:para id="p2300">Full blood count: anaemia. Platelet and white cell counts are often
                                    abnormal but may be elevated or lowered.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1605">
                                <ce:label>•</ce:label>
                                <ce:para id="p2305">Blood film shows anisocytosis, teardrop erythrocytes and immature
                                    neutrophils.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1610">
                                <ce:label>•</ce:label>
                                <ce:para id="p2310">Bone marrow: often very difficult to obtain aspirate ('dry tap').
                                    Biopsy shows extensive fibrosis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1615">
                                <ce:label>•</ce:label>
                                <ce:para id="p2315">Cytogenetics: may help estimate prognosis.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0615">
                    <ce:section-title id="st0615">Treatment</ce:section-title>
                    <ce:para id="p2320">
                        <ce:list id="l0365">
                            <ce:list-item id="u1620">
                                <ce:label>•</ce:label>
                                <ce:para id="p2325">Allogeneic stem cell transplant is the only curative treatment.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1625">
                                <ce:label>•</ce:label>
                                <ce:para id="p2330">Hydroxyurea is often effective at improving symptoms and reducing
                                    splenomegaly. Splenectomy may be required.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                    <ce:para id="p2335">Survival is very variable. In high-risk patients it may be as little as 1–2
                        years from diagnosis, but in low-risk patients may be as long as 20 years. The decision of
                        whether to proceed with stem cell transplant, taking into account the high mortality associated
                        with the treatment, is often very difficult.
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0620">
            <ce:section-title id="st0620">BLEEDING DISORDERS</ce:section-title>
            <ce:para id="p2340">An increased tendency to bleeding can result from abnormalities of platelets, the
                coagulation pathway or blood vessels. The differential diagnosis, clinical findings and investigation of
                these disorders are discussed in detail in<ce:intra-ref xlink:href="pii:B978-0-7234-3864-9.00028-9"
                                                                        id="ia0045">Ch. 28</ce:intra-ref>. Specific
                conditions and their management are considered here.
            </ce:para>
            <ce:section id="s0625">
                <ce:section-title id="st0625">Haemophilia A</ce:section-title>
                <ce:para id="p2345">Haemophilia A affects 1 in 8000 males. As an X-linked recessive inherited condition
                    it affects only males, although heterozygous females may experience mild symptoms.
                </ce:para>
                <ce:section id="s0630">
                    <ce:section-title id="st0630">Pathology</ce:section-title>
                    <ce:para id="p2350">There are many mutations to the factor VIII gene that may cause haemophilia. The
                        abnormal forms have reduced factor VIII activity. The condition is classified as mild, moderate
                        and severe depending on factor activity relative to normal (i.e. &lt;<ce:hsp sp="0.10"/>1%, 1–5%
                        or &gt;<ce:hsp sp="0.10"/>5%, respectively).
                    </ce:para>
                </ce:section>
                <ce:section id="s0635">
                    <ce:section-title id="st0635">Presentation</ce:section-title>
                    <ce:para id="p2355">
                        <ce:list id="l0370">
                            <ce:list-item id="u1630">
                                <ce:label>•</ce:label>
                                <ce:para id="p2360">Severity of bleeding correlates with level of factor VIII activity
                                    (lower levels correspond to more severe symptoms).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1635">
                                <ce:label>•</ce:label>
                                <ce:para id="p2365">Bleeding into joints (haemarthrosis) and muscles is common, and may
                                    be spontaneous or secondary to trauma.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1640">
                                <ce:label>•</ce:label>
                                <ce:para id="p2370">Recurrent haemarthroses and intramuscular haematomas cause long-term
                                    disability due to arthropathy and contractures.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1645">
                                <ce:label>•</ce:label>
                                <ce:para id="p2375">Haematuria and intracranial bleeding may occur.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1650">
                                <ce:label>•</ce:label>
                                <ce:para id="p2380">Bleeding from small cuts is usually minor due to normal platelet
                                    function.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1655">
                                <ce:label>•</ce:label>
                                <ce:para id="p2385">After trauma, bleeding is out of proportion and often delayed.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0640">
                    <ce:section-title id="st0640">Investigations</ce:section-title>
                    <ce:para id="p2390">
                        <ce:list id="l0375">
                            <ce:list-item id="u1660">
                                <ce:label>•</ce:label>
                                <ce:para id="p2395">APTT (activated partial thromboplastin time): prolonged; normalizes
                                    with addition of 50% normal plasma.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1665">
                                <ce:label>•</ce:label>
                                <ce:para id="p2400">PT (prothrombin time): normal.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1670">
                                <ce:label>•</ce:label>
                                <ce:para id="p2405">Bleeding time: normal.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1675">
                                <ce:label>•</ce:label>
                                <ce:para id="p2410">Factor VIII assay: low.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0645">
                    <ce:section-title id="st0645">Treatment</ce:section-title>
                    <ce:para id="p2415">
                        <ce:list id="l0380">
                            <ce:list-item id="u1680">
                                <ce:label>•</ce:label>
                                <ce:para id="p2420">Usually managed in specialized haemophilia centres.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1685">
                                <ce:label>•</ce:label>
                                <ce:para id="p2425">When there is bleeding or the patient requires surgery, factor VIII
                                    levels can be increased in two ways – mild haemophilia with desmopressin (DDAVP);
                                    moderate or severe haemophilia with recombinant factor VIII concentrates.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1690">
                                <ce:label>•</ce:label>
                                <ce:para id="p2430">Other aspects of management include analgesia (avoiding aspirin),
                                    joint replacement, synovectomy for arthropathy, regular dental care, and
                                    psychosocial and genetic support.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0650">
                    <ce:section-title id="st0650">Prognosis and complications</ce:section-title>
                    <ce:para id="p2435">Life expectancy should be normal with current therapies. Previously the
                        complications of receiving factor VIII concentrates included exposure to HIV, hepatitis B and C
                        as it was derived from donated blood. This is much reduced with recombinant factor VIII. The
                        development of inhibitors to infused factor VIII results in a much worse prognosis.
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0655">
                <ce:section-title id="st0655">Haemophilia B (Christmas disease)</ce:section-title>
                <ce:para id="p2440">Incidence is 1 per 30 000. It is also an X-linked recessive inherited condition.
                    There is decreased plasma factor IX activity. The clinical features are identical to haemophilia A.
                </ce:para>
                <ce:section id="s0660">
                    <ce:section-title id="st0660">Investigations</ce:section-title>
                    <ce:para id="p2445">
                        <ce:list id="l0385">
                            <ce:list-item id="u1695">
                                <ce:label>•</ce:label>
                                <ce:para id="p2450">APTT: prolonged.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1700">
                                <ce:label>•</ce:label>
                                <ce:para id="p2455">PT: normal.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1705">
                                <ce:label>•</ce:label>
                                <ce:para id="p2460">Bleeding time: normal.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1710">
                                <ce:label>•</ce:label>
                                <ce:para id="p2465">Factor IX assay: low.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0665">
                    <ce:section-title id="st0665">Treatment</ce:section-title>
                    <ce:para id="p2470">Treatment is with recombinant factor IX. Desmopressin has no effect on factor IX
                        levels. Otherwise, treatment is the same as for haemophilia A. With current therapies life
                        expectancy should be normal.
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0670">
                <ce:section-title id="st0670">Von Willebrand's disease</ce:section-title>
                <ce:para id="p2475">Von Willebrand's disease (vWD) occurs in 1% of the general population. It is an
                    inherited (autosomal dominant) condition.
                </ce:para>
                <ce:section id="s0675">
                    <ce:section-title id="st0675">Pathology</ce:section-title>
                    <ce:para id="p2480">
                        <ce:list id="l0390">
                            <ce:list-item id="u1715">
                                <ce:label>•</ce:label>
                                <ce:para id="p2485">Deficiency of von Willebrand factor (vWF).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1720">
                                <ce:label>•</ce:label>
                                <ce:para id="p2490">vWF is a plasma protein that mediates platelet adherence to the
                                    subendothelium and platelet aggregation. It also binds and stabilizes factor VIII.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0680">
                    <ce:section-title id="st0680">Presentation</ce:section-title>
                    <ce:para id="p2495">
                        <ce:list id="l0395">
                            <ce:list-item id="u1725">
                                <ce:label>•</ce:label>
                                <ce:para id="p2500">Both sexes are equally affected.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1730">
                                <ce:label>•</ce:label>
                                <ce:para id="p2505">Severity of disease is variable.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1735">
                                <ce:label>•</ce:label>
                                <ce:para id="p2510">Most patients present with bleeding similar to platelet disorders:
                                    bruising, bleeding into the skin, mucosal bleeding (epistaxis, bleeding gums,
                                    gastrointestinal bleeding).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1740">
                                <ce:label>•</ce:label>
                                <ce:para id="p2515">Menorrhagia and bleeding following surgery, dental extractions,
                                    trauma and delivery are common.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1745">
                                <ce:label>•</ce:label>
                                <ce:para id="p2520">In some patients binding to factor VIII is affected, resulting in
                                    low factor VIII levels and a clinical picture similar to haemophilia.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0685">
                    <ce:section-title id="st0685">Investigations</ce:section-title>
                    <ce:para id="p2525">
                        <ce:list id="l0400">
                            <ce:list-item id="u1750">
                                <ce:label>•</ce:label>
                                <ce:para id="p2530">Platelets: normal in number and structure.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1755">
                                <ce:label>•</ce:label>
                                <ce:para id="p2535">APTT: prolonged (may be normal).</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1760">
                                <ce:label>•</ce:label>
                                <ce:para id="p2540">PTT: normal.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1765">
                                <ce:label>•</ce:label>
                                <ce:para id="p2545">Prolonged bleeding time and elevated platelet function analyser
                                    result.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1770">
                                <ce:label>•</ce:label>
                                <ce:para id="p2550">vWF assays: low.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0690">
                    <ce:section-title id="st0690">Treatment</ce:section-title>
                    <ce:para id="p2555">Aspirin should be avoided. Treatment is with desmopressin, tranexamic acid or
                        plasma-derived factor VIII concentrates (which contain large amounts of vWf) in haemorrhage or
                        perioperatively. Life expectancy is usually normal.
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0695">
                <ce:section-title id="st0695">Immune thrombocytopenia (ITP)</ce:section-title>
                <ce:para id="p2560">In ITP, thrombocytopenia results from antibody-mediated destruction of platelets in
                    the spleen and liver. It affects both adults and children, with an incidence in adults of around 40
                    cases per million. The cause is often unclear, but it may occur following viral illnesses, in the
                    context of other autoimmune disease (such as SLE) or lymphoproliferative disease, or following
                    administration of certain drugs. When there is an underlying cause it is termed 'secondary' ITP.
                </ce:para>
                <ce:section id="s0700">
                    <ce:section-title id="st0700">Clinical features</ce:section-title>
                    <ce:para id="p2565">
                        <ce:list id="l0405">
                            <ce:list-item id="u1775">
                                <ce:label>•</ce:label>
                                <ce:para id="p2570">Easy bruising, petechial or purpuric rash.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1780">
                                <ce:label>•</ce:label>
                                <ce:para id="p2575">Mucosal bleeding and menorrhagia.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1785">
                                <ce:label>•</ce:label>
                                <ce:para id="p2580">Haematuria and gastrointestinal bleeding is uncommon.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1790">
                                <ce:label>•</ce:label>
                                <ce:para id="p2585">Splenomegaly is rarely present in isolated ITP and should prompt
                                    consideration of an underlying diagnosis.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0705">
                    <ce:section-title id="st0705">Investigations</ce:section-title>
                    <ce:para id="p2590">
                        <ce:list id="l0410">
                            <ce:list-item id="u1795">
                                <ce:label>•</ce:label>
                                <ce:para id="p2595">Full blood count: isolated thrombocytopenia, or anaemia if
                                    significant bleeding.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1800">
                                <ce:label>•</ce:label>
                                <ce:para id="p2600">Blood film: platelet clumps in pseudothrombocytopenia due to
                                    EDTA-mediated aggregation. The sample should be repeated in a citrate or heparin
                                    tube.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1805">
                                <ce:label>•</ce:label>
                                <ce:para id="p2605">Bone marrow examination: required in older patients, when systemic
                                    symptoms are present, or if there are other cytopenias that are not easily
                                    explained.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0710">
                    <ce:section-title id="st0710">Treatment</ce:section-title>
                    <ce:para id="p2610">It may be difficult to know when to start treatment. Generally, if patients are
                        symptomatic and platelets are below 30<ce:hsp sp="0.12"/>×<ce:hsp sp="0.12"/>10<ce:sup>
                            9</ce:sup>/L, treatment is required. Otherwise, careful monitoring and advice may be
                        sufficient.
                        <ce:list id="l0415">
                            <ce:list-item id="u1810">
                                <ce:label>•</ce:label>
                                <ce:para id="p2615">Transfused platelets are rapidly destroyed and should only be given
                                    in significant acute bleeding.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1815">
                                <ce:label>•</ce:label>
                                <ce:para id="p2620">IV immunoglobulin will rapidly (but temporarily) raise the platelet
                                    count.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1820">
                                <ce:label>•</ce:label>
                                <ce:para id="p2625">High-dose oral prednisolone achieves a response in up to 75%.
                                    Steroids should be withdrawn slowly.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1825">
                                <ce:label>•</ce:label>
                                <ce:para id="p2630">Splenectomy or other immunosuppressive therapy may be required if
                                    relapse occurs.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0715">
            <ce:section-title id="st0715">DISSEMINATED INTRAVASCULAR COAGULATION</ce:section-title>
            <ce:para id="p2635">This is a syndrome characterized by a specific haematological response to a wide range
                of insults.
            </ce:para>
            <ce:section id="s0720">
                <ce:section id="s0725">
                    <ce:section-title id="st0720">Aetiology</ce:section-title>
                    <ce:para id="p2640">DIC may be caused by:
                        <ce:list id="l0420">
                            <ce:list-item id="u1830">
                                <ce:label>•</ce:label>
                                <ce:para id="p2645">Malignancy: mucus-secreting adenocarcinomas, prostate, pancreatic
                                    carcinoma, acute promyelocytic leukaemia (AML–M3).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1835">
                                <ce:label>•</ce:label>
                                <ce:para id="p2650">Infection: Gram-negative (most commonly) or Gram-positive sepsis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1840">
                                <ce:label>•</ce:label>
                                <ce:para id="p2655">Obstetric: amniotic fluid embolism, placental abruption,
                                    pre-eclampsia, HELLP syndrome, septic abortion.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1845">
                                <ce:label>•</ce:label>
                                <ce:para id="p2660">Tissue damage: rhabdomyolysis, fat embolism, severe trauma, burns.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1850">
                                <ce:label>•</ce:label>
                                <ce:para id="p2665">Immunological: incompatible blood transfusion, drug reaction,
                                    anaphylaxis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1855">
                                <ce:label>•</ce:label>
                                <ce:para id="p2670">Liver disease: acute fatty liver of pregnancy, fulminant liver
                                    failure.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1860">
                                <ce:label>•</ce:label>
                                <ce:para id="p2675">Others: snake bites, acute pancreatitis.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0730">
                    <ce:section-title id="st0725">Pathology</ce:section-title>
                    <ce:para id="p2680">
                        <ce:list id="l0425">
                            <ce:list-item id="u1865">
                                <ce:label>•</ce:label>
                                <ce:para id="p2685">Initially, intravascular coagulation is precipitated by release of
                                    tissue factor or procoagulant substances into the circulation from injured cells,
                                    malignant cells, or damaged endothelium.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1870">
                                <ce:label>•</ce:label>
                                <ce:para id="p2690">Microthrombi form throughout the microcirculation causing ischaemia
                                    and infarction.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1875">
                                <ce:label>•</ce:label>
                                <ce:para id="p2695">Platelets, fibrin and clotting factors are consumed by the
                                    thrombotic process and the fibrinolytic system becomes activated; these two
                                    processes result in a tendency to bleed, and haemorrhage may be significant.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0735">
                    <ce:section-title id="st0730">Presentation</ce:section-title>
                    <ce:para id="p2700">
                        <ce:list id="l0430">
                            <ce:list-item id="u1880">
                                <ce:label>•</ce:label>
                                <ce:para id="p2705">DIC is often severe and life-threatening, but may be chronic and
                                    compensated when due to malignancy.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1885">
                                <ce:label>•</ce:label>
                                <ce:para id="p2710">Thrombosis can cause widespread ischaemia or infarction leading to
                                    renal failure, liver failure and CNS involvement.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1890">
                                <ce:label>•</ce:label>
                                <ce:para id="p2715">Bleeding is often into the skin or from recent venepuncture sites.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1895">
                                <ce:label>•</ce:label>
                                <ce:para id="p2720">Gastrointestinal and pulmonary haemorrhage may also occur.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0740">
                    <ce:section-title id="st0735">Investigations</ce:section-title>
                    <ce:para id="p2725">
                        <ce:list id="l0435">
                            <ce:list-item id="u1900">
                                <ce:label>•</ce:label>
                                <ce:para id="p2730">Platelet count: low.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1905">
                                <ce:label>•</ce:label>
                                <ce:para id="p2735">PT and APTT: prolonged.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1910">
                                <ce:label>•</ce:label>
                                <ce:para id="p2740">Fibrinogen: usually low (may be normal as acute phase reactant).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1915">
                                <ce:label>•</ce:label>
                                <ce:para id="p2745">D-dimers/fibrin degradation products: high.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1920">
                                <ce:label>•</ce:label>
                                <ce:para id="p2750">Blood film: fragmented RBCs due to microangiopathic haemolysis.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0745">
                    <ce:section-title id="st0740">Treatment</ce:section-title>
                    <ce:para id="p2755">
                        <ce:list id="l0440">
                            <ce:list-item id="u1925">
                                <ce:label>•</ce:label>
                                <ce:para id="p2760">Treatment of the underlying disease is the first priority and may
                                    resolve the DIC.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1930">
                                <ce:label>•</ce:label>
                                <ce:para id="p2765">Meticulous supportive care (e.g. fluids, antibiotics, debridement of
                                    gangrene).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1935">
                                <ce:label>•</ce:label>
                                <ce:para id="p2770">Replacement of platelets and clotting factors (using fresh frozen
                                    plasma or cryoprecipitate) may be used if there is haemorrhage or risk of
                                    haemorrhage (e.g. in surgery).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1940">
                                <ce:label>•</ce:label>
                                <ce:para id="p2775">Pharmacological inhibitors of coagulation or fibrinolysis (e.g.
                                    heparin or tranexamic acid) may be beneficial in certain circumstances but their use
                                    is controversial.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0750">
                    <ce:section-title id="st0745">Prognosis</ce:section-title>
                    <ce:para id="p2780">Mortality is up to 80% in severe DIC and is usually due to the underlying
                        disease.
                        <ce:display>
                            <ce:textbox role="alt1" id="b0035">
                                <ce:textbox-head>
                                    <ce:title>COMMUNICATION</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p2785">Raised total protein with a normal albumin level should
                                            raise suspicion of the presence of a paraprotein.
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0755">
            <ce:section-title id="st0750">THROMBOTIC DISORDERS AND THROMBOEMBOLISM</ce:section-title>
            <ce:para id="p2790">
                <ce:display>
                    <ce:textbox role="alt0" id="b0040">
                        <ce:textbox-head>
                            <ce:title>HINTS AND TIPS</ce:title>
                        </ce:textbox-head>
                        <ce:textbox-body>
                            <ce:sections>
                                <ce:para id="p2795">The causes of thromboembolism can be broken down by Virchow's triad:
                                    <ce:list id="l0445">
                                        <ce:list-item id="u1945">
                                            <ce:label>•</ce:label>
                                            <ce:para id="p2800">Changes in the vessel wall.</ce:para>
                                        </ce:list-item>
                                        <ce:list-item id="u1950">
                                            <ce:label>•</ce:label>
                                            <ce:para id="p2805">Changes in the blood flow.</ce:para>
                                        </ce:list-item>
                                        <ce:list-item id="u1955">
                                            <ce:label>•</ce:label>
                                            <ce:para id="p2810">Changes in the composition of the blood.</ce:para>
                                        </ce:list-item>
                                    </ce:list>
                                </ce:para>
                            </ce:sections>
                        </ce:textbox-body>
                    </ce:textbox>
                </ce:display>
            </ce:para>
            <ce:para id="p2815">Thromboembolism is common, and the increased incidence of deep vein thrombosis following
                long journeys (so-called 'economy class syndrome') has made it a well-known area among the public.
            </ce:para>
            <ce:section id="s0760">
                <ce:section id="s0765">
                    <ce:section-title id="st0755">Aetiology</ce:section-title>
                    <ce:para id="p2820">Risk factors for venous thromboembolism are outlined in
                        <ce:cross-ref refid="f0065">Fig. 37.12</ce:cross-ref>
                        <ce:float-anchor refid="f0065"/>.
                    </ce:para>
                </ce:section>
                <ce:section id="s0770">
                    <ce:section-title id="st0760">Pathology</ce:section-title>
                    <ce:para id="p2825">
                        <ce:list id="l0450">
                            <ce:list-item id="u1960">
                                <ce:label>•</ce:label>
                                <ce:para id="p2830">Venous thrombosis can be caused by abnormal vessel walls, venous
                                    stasis or hypercoagulable blood.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1965">
                                <ce:label>•</ce:label>
                                <ce:para id="p2835">Thrombosis may be precipitated by a specific provoking event such as
                                    surgery or a physiological state such as pregnancy.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1970">
                                <ce:label>•</ce:label>
                                <ce:para id="p2840">The lower limbs are the most common site of thrombosis.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1975">
                                <ce:label>•</ce:label>
                                <ce:para id="p2845">Small clots may break off and cause pulmonary embolus or, very
                                    rarely, cerebral infarction by paradoxical embolus in patients with a patent foramen
                                    ovale.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0775">
                    <ce:section-title id="st0765">Presentation</ce:section-title>
                    <ce:para id="p2850">
                        <ce:list id="l0455">
                            <ce:list-item id="u1980">
                                <ce:label>•</ce:label>
                                <ce:para id="p2855">Deep vein thrombosis (DVT) causes local pain, swelling, redness and
                                    oedema.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1985">
                                <ce:label>•</ce:label>
                                <ce:para id="p2860">The diagnosis can be difficult to make on clinical grounds.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1990">
                                <ce:label>•</ce:label>
                                <ce:para id="p2865">Pulmonary embolus (PE) causes sudden onset of pleuritic chest pain,
                                    dyspnoea and haemoptysis.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u1995">
                                <ce:label>•</ce:label>
                                <ce:para id="p2870">Patients with inherited hypercoagulable states may present with
                                    venous thromboses without obvious precipitants, in unusual places (e.g. Budd–Chiari
                                    syndrome), at an early age or with spontaneous abortions.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2000">
                                <ce:label>•</ce:label>
                                <ce:para id="p2875">Antiphospholipid syndrome and hyperhomocysteinaemia increase the
                                    risk of arterial as well as venous thromboses.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0780">
                    <ce:section-title id="st0770">Investigations</ce:section-title>
                    <ce:para id="p2880">
                        <ce:list id="l0460">
                            <ce:list-item id="u2005">
                                <ce:label>•</ce:label>
                                <ce:para id="p2885">Careful clinical examination should be performed to look for an
                                    underlying cause such as malignancy, and investigations requested appropriately.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2010">
                                <ce:label>•</ce:label>
                                <ce:para id="p2890">The pre-test probability of VTE should be evaluated with an accepted
                                    scoring system.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2015">
                                <ce:label>•</ce:label>
                                <ce:para id="p2895">In cases where the risk score is low or equivocal, D-dimer
                                    measurement may be helpful. It is a sensitive but non-specific test, and helps to
                                    exclude DVT.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2020">
                                <ce:label>•</ce:label>
                                <ce:para id="p2900">The final step is to perform the appropriate imaging test on the
                                    at-risk patients. This may be ultrasound, ventilation–perfusion scanning or CT
                                    pulmonary angiography (CTPA).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2025">
                                <ce:label>•</ce:label>
                                <ce:para id="p2905">A baseline platelet count and clotting screen should always be
                                    performed.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2030">
                                <ce:label>•</ce:label>
                                <ce:para id="p2910">If the patient is young, ask if there have been recurrent episodes,
                                    recurrent spontaneous abortions or a family history of thromboembolism, and consider
                                    hereditary thrombophilia. Assays are available to detect these abnormalities.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0785">
                    <ce:section-title id="st0775">Treatment if thrombosis is proven</ce:section-title>
                    <ce:para id="p2915">
                        <ce:list id="l0465">
                            <ce:list-item id="u2035">
                                <ce:label>•</ce:label>
                                <ce:para id="p2920">Anticoagulation with low-molecular-weight heparin should be started.
                                    It is licensed for both DVT and PE. The lack of need for monitoring has allowed the
                                    treatment of DVT as an outpatient. The indications for unfractionated heparin are
                                    decreasing; among them are renal failure or mechanical heart valves.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2040">
                                <ce:label>•</ce:label>
                                <ce:para id="p2925">Oral warfarin should be given simultaneously and monitored using the
                                    international normalized ratio (INR), which should be maintained between 2 and 3.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2045">
                                <ce:label>•</ce:label>
                                <ce:para id="p2930">Heparin should be continued until the INR is therapeutic.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2050">
                                <ce:label>•</ce:label>
                                <ce:para id="p2935">If heparin is contraindicated, agents such as the hirudins or
                                    fondaparinux can be used.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2055">
                                <ce:label>•</ce:label>
                                <ce:para id="p2940">Newer oral anticoagulants, such as dabigatran and rivaroxaban, are
                                    being introduced in certain contexts and may eventually replace warfarin completely.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                        <ce:display>
                            <ce:textbox role="alt0" id="b0045">
                                <ce:textbox-head>
                                    <ce:title>HINTS AND TIPS</ce:title>
                                </ce:textbox-head>
                                <ce:textbox-body>
                                    <ce:sections>
                                        <ce:para id="p2945">Warfarin alone is initially PROcoagulant due to its more
                                            rapid inhibition of PROtein C and S.
                                        </ce:para>
                                    </ce:sections>
                                </ce:textbox-body>
                            </ce:textbox>
                        </ce:display>
                    </ce:para>
                </ce:section>
                <ce:section id="s0790">
                    <ce:section-title id="st0780">Treatment period</ce:section-title>
                    <ce:para id="p2950">The length of time a patient should be anticoagulated is controversial and
                        always under review, but as a general rule is 3–6 months depending on the extent and the
                        existence of a precipitating factor such as a period of immobilization.
                    </ce:para>
                    <ce:para id="p2955">Above-knee DVTs are at increased risk of propagating along the venous system and
                        embolizing to the lungs. Two or more thromboses, whether provoked or unprovoked, indicate that
                        lifelong anticoagulation is required.
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
        <ce:section id="s0795">
            <ce:section-title id="st0785">THROMBOTIC THROMBOCYTOPENIC PURPURA AND HAEMOLYTIC URAEMIC SYNDROME
            </ce:section-title>
            <ce:para id="p2960">These two conditions are characterized by thrombosis and microangiopathic haemolytic
                anaemia. They share several features and are often considered together. Mortality is up to 80% without
                treatment.
            </ce:para>
            <ce:section id="s0800">
                <ce:section-title id="st0790">Haemolytic uraemic syndrome (HUS)</ce:section-title>
                <ce:para id="p2965">HUS is most common in children, and 90% of cases occur following a diarrhoeal
                    illness, particularly with pathogenic<ce:italic>Escherichia coli</ce:italic>. The remaining 10% can
                    be due to a variety of causes including viruses, drugs and cancer. Complement abnormalities may
                    underpin the pathogenesis.
                </ce:para>
                <ce:section id="s0805">
                    <ce:section-title id="st0795">Clinical features</ce:section-title>
                    <ce:para id="p2970">The cardinal features of HUS are acute kidney injury, thrombocytopenia and
                        haemolytic anaemia. Involvement of other organs, particularly the liver and CNS, occurs in up to
                        20%.
                    </ce:para>
                </ce:section>
                <ce:section id="s0810">
                    <ce:section-title id="st0800">Investigations</ce:section-title>
                    <ce:para id="p2975">
                        <ce:list id="l0470">
                            <ce:list-item id="u2060">
                                <ce:label>•</ce:label>
                                <ce:para id="p2980">Haematology: anaemia, thrombocytopenia DAT negative.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2065">
                                <ce:label>•</ce:label>
                                <ce:para id="p2985">Biochemistry: renal impairment, raised LDH, raised bilirubin.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2070">
                                <ce:label>•</ce:label>
                                <ce:para id="p2990">Blood film: red cell fragments, reticulocytes.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2075">
                                <ce:label>•</ce:label>
                                <ce:para id="p2995">Coagulation studies: normal (as opposed to DIC).</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0815">
                    <ce:section-title id="st0805">Treatment</ce:section-title>
                    <ce:para id="p3000">
                        <ce:list id="l0475">
                            <ce:list-item id="u2080">
                                <ce:label>•</ce:label>
                                <ce:para id="p3005">Typical HUS (following diarrhoea) is usually self-resolving with
                                    supportive care. Dialysis is sometimes required.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2085">
                                <ce:label>•</ce:label>
                                <ce:para id="p3010">Plasma exchange or immunosuppression may be required.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2090">
                                <ce:label>•</ce:label>
                                <ce:para id="p3015">Eculizumab (anti-complement) may be effective.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
            </ce:section>
            <ce:section id="s0820">
                <ce:section-title id="st0810">Thrombotic thrombocytopenic purpura</ce:section-title>
                <ce:para id="p3020">Thrombotic thrombocytopenic purpura (TTP) is a rare disease, most common in young
                    adults. It is a combination of signs, symptoms and characteristic blood film appearance. Reduced
                    ADAMTS-13 (a metalloproteinase) activity allows large von Willebrand factor multimers to enter the
                    circulation, causing platelet aggregation and microthrombi.
                </ce:para>
                <ce:section id="s0825">
                    <ce:section-title id="st0815">Clinical features</ce:section-title>
                    <ce:para id="p3025">The classical 'pentad' consists of:
                        <ce:list id="l0480">
                            <ce:list-item id="u2095">
                                <ce:label>•</ce:label>
                                <ce:para id="p3030">Haemolytic anaemia: typical symptoms.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2100">
                                <ce:label>•</ce:label>
                                <ce:para id="p3035">Thrombocytopenia: bleeding.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2105">
                                <ce:label>•</ce:label>
                                <ce:para id="p3040">Acute kidney injury.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2110">
                                <ce:label>•</ce:label>
                                <ce:para id="p3045">Prominent neurological features such as lethargy, headache,
                                    confusion and seizures.
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2115">
                                <ce:label>•</ce:label>
                                <ce:para id="p3050">Pyrexia that is not caused by infection.</ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                    <ce:para id="p3055">These features may not all be present and clinical suspicion is necessary.
                    </ce:para>
                </ce:section>
                <ce:section id="s0830">
                    <ce:section-title id="st0820">Investigations</ce:section-title>
                    <ce:para id="p3060">
                        <ce:list id="l0485">
                            <ce:list-item id="u2120">
                                <ce:label>•</ce:label>
                                <ce:para id="p3065">Blood film: anaemia, reticulocytosis, thrombocytopenia and
                                    fragmented red cells (schistocytes).
                                </ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2125">
                                <ce:label>•</ce:label>
                                <ce:para id="p3070">Bilirubin and LDH: increased due to haemolysis.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2130">
                                <ce:label>•</ce:label>
                                <ce:para id="p3075">Coagulation: usually normal.</ce:para>
                            </ce:list-item>
                            <ce:list-item id="u2135">
                                <ce:label>•</ce:label>
                                <ce:para id="p3080">ADAMTS-13 assays are available but take too long to help with
                                    diagnosis.
                                </ce:para>
                            </ce:list-item>
                        </ce:list>
                    </ce:para>
                </ce:section>
                <ce:section id="s0835">
                    <ce:section-title id="st0825">Treatment</ce:section-title>
                    <ce:para id="p3085">Plasma exchange has vastly improved the prognosis and most people achieve a
                        lasting response. Immunosuppression is also used.
                    </ce:para>
                </ce:section>
            </ce:section>
        </ce:section>
    </ce:sections>
    <ce:further-reading id="fr0010">
        <ce:section-title id="st0830">Further reading</ce:section-title>
        <ce:further-reading-sec id="fs0010">
            <ce:bib-reference id="bb0010">
                <ce:label>Bird et al., 2011</ce:label>
                <sb:reference id="rf0010">
                    <sb:contribution>
                        <sb:authors>
                            <sb:author>
                                <ce:given-name>J.</ce:given-name>
                                <ce:surname>Bird</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>R.</ce:given-name>
                                <ce:surname>Owen</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>S.</ce:given-name>
                                <ce:surname>D'Sa</ce:surname>
                            </sb:author>
                            <sb:et-al/>
                        </sb:authors>
                        <sb:title>
                            <sb:maintitle>Guidelines for the diagnosis and management of multiple myeloma</sb:maintitle>
                        </sb:title>
                    </sb:contribution>
                    <sb:host>
                        <sb:issue>
                            <sb:series>
                                <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                </sb:title>
                                <sb:volume-nr>154</sb:volume-nr>
                            </sb:series>
                            <sb:date>2011</sb:date>
                        </sb:issue>
                        <sb:pages>
                            <sb:first-page>32</sb:first-page>
                            <sb:last-page>75</sb:last-page>
                        </sb:pages>
                    </sb:host>
                </sb:reference>
            </ce:bib-reference>
            <ce:bib-reference id="bb0015">
                <ce:label>British Society for Haematology, n.d</ce:label>
                <ce:other-ref id="or0010">
                    <ce:textref id="tr0010">British Society for Haematology: publishes guidelines and reviews of all
                        aspects of haematology. Available online at:<ce:inter-ref xlink:href="http://www.b-s-h.org.uk"
                                                                                  id="ir0010">
                            http://www.b-s-h.org.uk</ce:inter-ref>.
                    </ce:textref>
                </ce:other-ref>
            </ce:bib-reference>
            <ce:bib-reference id="bb0020">
                <ce:label>Campbell and Green, 2006</ce:label>
                <sb:reference id="rf0015">
                    <sb:contribution>
                        <sb:authors>
                            <sb:author>
                                <ce:given-name>P.</ce:given-name>
                                <ce:surname>Campbell</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>A.</ce:given-name>
                                <ce:surname>Green</ce:surname>
                            </sb:author>
                        </sb:authors>
                        <sb:title>
                            <sb:maintitle>The myeloproliferative disorders</sb:maintitle>
                        </sb:title>
                    </sb:contribution>
                    <sb:host>
                        <sb:issue>
                            <sb:series>
                                <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                </sb:title>
                                <sb:volume-nr>355</sb:volume-nr>
                            </sb:series>
                            <sb:date>2006</sb:date>
                        </sb:issue>
                        <sb:pages>
                            <sb:first-page>2452</sb:first-page>
                            <sb:last-page>2466</sb:last-page>
                        </sb:pages>
                    </sb:host>
                </sb:reference>
            </ce:bib-reference>
            <ce:bib-reference id="bb0025">
                <ce:label>Campo et al., 2011</ce:label>
                <sb:reference id="rf0020">
                    <sb:contribution>
                        <sb:authors>
                            <sb:author>
                                <ce:given-name>E.</ce:given-name>
                                <ce:surname>Campo</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>S.</ce:given-name>
                                <ce:surname>Swerdlow</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>N.</ce:given-name>
                                <ce:surname>Harris</ce:surname>
                            </sb:author>
                            <sb:et-al/>
                        </sb:authors>
                        <sb:title>
                            <sb:maintitle>The 2008 WHO classification of lymphoid neoplasms and beyond: evolving
                                concepts and practical applications
                            </sb:maintitle>
                        </sb:title>
                    </sb:contribution>
                    <sb:host>
                        <sb:issue>
                            <sb:series>
                                <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                </sb:title>
                                <sb:volume-nr>117</sb:volume-nr>
                            </sb:series>
                            <sb:date>2011</sb:date>
                        </sb:issue>
                        <sb:pages>
                            <sb:first-page>5019</sb:first-page>
                            <sb:last-page>5032</sb:last-page>
                        </sb:pages>
                    </sb:host>
                </sb:reference>
            </ce:bib-reference>
            <ce:bib-reference id="bb0030">
                <ce:label>National Institute for Health, 2011</ce:label>
                <sb:reference id="rf0025">
                    <sb:contribution>
                        <sb:authors>
                            <sb:author>
                                <ce:surname>National Institute for Health and Clinical Excellence (NICE)</ce:surname>
                            </sb:author>
                        </sb:authors>
                        <sb:title>
                            <sb:maintitle>Anaemia management in people with chronic kidney disease. Clinical guideline
                                CG114
                            </sb:maintitle>
                        </sb:title>
                    </sb:contribution>
                    <sb:host>
                        <sb:book>
                            <sb:date>2011</sb:date>
                        </sb:book>
                    </sb:host>
                    <sb:host>
                        <sb:e-host>
                            <ce:inter-ref id="ir0015" xlink:href="http://www.nice.org.uk/CG114">
                                http://www.nice.org.uk/CG114
                            </ce:inter-ref>
                        </sb:e-host>
                    </sb:host>
                    <sb:comment>Available online at</sb:comment>
                </sb:reference>
            </ce:bib-reference>
            <ce:bib-reference id="bb0035">
                <ce:label>Noris and Remuzzi, 2009</ce:label>
                <sb:reference id="rf0030">
                    <sb:contribution>
                        <sb:authors>
                            <sb:author>
                                <ce:given-name>M.</ce:given-name>
                                <ce:surname>Noris</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>G.</ce:given-name>
                                <ce:surname>Remuzzi</ce:surname>
                            </sb:author>
                        </sb:authors>
                        <sb:title>
                            <sb:maintitle>Atypical haemolytic uraemic syndrome</sb:maintitle>
                        </sb:title>
                    </sb:contribution>
                    <sb:host>
                        <sb:issue>
                            <sb:series>
                                <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                </sb:title>
                                <sb:volume-nr>361</sb:volume-nr>
                            </sb:series>
                            <sb:date>2009</sb:date>
                        </sb:issue>
                        <sb:pages>
                            <sb:first-page>1676</sb:first-page>
                            <sb:last-page>1687</sb:last-page>
                        </sb:pages>
                    </sb:host>
                </sb:reference>
            </ce:bib-reference>
            <ce:bib-reference id="bb0040">
                <ce:label>Reed et al., 2010</ce:label>
                <sb:reference id="rf0035">
                    <sb:contribution>
                        <sb:authors>
                            <sb:author>
                                <ce:given-name>D.</ce:given-name>
                                <ce:surname>Reed</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>T.</ce:given-name>
                                <ce:surname>Williams</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>M.</ce:given-name>
                                <ce:surname>Gladwin</ce:surname>
                            </sb:author>
                        </sb:authors>
                        <sb:title>
                            <sb:maintitle>Sickle-cell disease</sb:maintitle>
                        </sb:title>
                    </sb:contribution>
                    <sb:host>
                        <sb:issue>
                            <sb:series>
                                <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                </sb:title>
                                <sb:volume-nr>376</sb:volume-nr>
                            </sb:series>
                            <sb:date>2010</sb:date>
                        </sb:issue>
                        <sb:pages>
                            <sb:first-page>2019</sb:first-page>
                            <sb:last-page>2031</sb:last-page>
                        </sb:pages>
                    </sb:host>
                </sb:reference>
            </ce:bib-reference>
            <ce:bib-reference id="bb0045">
                <ce:label>Tefferi and Vardiman, 2009</ce:label>
                <sb:reference id="rf0040">
                    <sb:contribution>
                        <sb:authors>
                            <sb:author>
                                <ce:given-name>A.</ce:given-name>
                                <ce:surname>Tefferi</ce:surname>
                            </sb:author>
                            <sb:author>
                                <ce:given-name>J.</ce:given-name>
                                <ce:surname>Vardiman</ce:surname>
                            </sb:author>
                        </sb:authors>
                        <sb:title>
                            <sb:maintitle>Myelodysplastic syndromes</sb:maintitle>
                        </sb:title>
                    </sb:contribution>
                    <sb:host>
                        <sb:issue>
                            <sb:series>
                                <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                </sb:title>
                                <sb:volume-nr>361</sb:volume-nr>
                            </sb:series>
                            <sb:date>2009</sb:date>
                        </sb:issue>
                        <sb:pages>
                            <sb:first-page>1872</sb:first-page>
                            <sb:last-page>1885</sb:last-page>
                        </sb:pages>
                    </sb:host>
                </sb:reference>
            </ce:bib-reference>
        </ce:further-reading-sec>
    </ce:further-reading>
</chapter>